**Name of Journal: *World Journal of Gastrointestinal Oncology***

**ESPS Manuscript NO: 25452**

**Manuscript Type: Review**

**Robotic rectal surgery: State of the art**

Staderini F *et al.* Robotic rectal surgery

**Fabio Staderini, Foppa Caterina, Minuzzo Alessio, Badii Benedetta, Qirici Etleva**, **Perigli Giuliano, Trallori Giacomo, Mallardi Beatrice, Lami Gabriele, Macrì Giuseppe, Bonanomi Andrea, Bagnoli Siro, Perigli Giuliano, Cianchi Fabio**

**Staderini Fabio, Foppa Caterina, Minuzzo Alessio, Badii Benedetta, Qirici Etleva**, **Perigli Giuliano,** **Cianchi Fabio,** Center of Oncological Minimally Invasive Surgery, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy

**Trallori Giacomo, Perigli Giuliano,** Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy

**Mallardi Beatrice,** ISPO, 50134 Florence, Italy

**Lami Gabriele, Macrì Giuseppe,** Department of Experimental and Clinical Biomedical Sciences, University of Florence, 5134 Florence, Italy

**Bonanomi Andrea, Bagnoli Siro,** Unit of Gastroenterology, AOU Careggi, 50134 Florence, Italy

**Author contributions:** All the authors contributed to the data collection.

 **Conflict-of-interest** **statement:** Authors declare no conflict of interest for this article. Authors declare no instance of Plagiarism or Academic Misconduct.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Cianchi Fabio, MD,** Center of Oncological Minimally Invasive Surgery, Department of Surgery and Translational Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy. fabio.cianchi@unifi.it

**Telephone:** +39-33-9307447

**Received:** March 10, 2016

**Peer-review started:** March 15, 2016

**First decision:** May 19, 2016

**Revised:** July 12, 2016

**Accepted:** August 27, 2016

**Article in press:**

**Published online:**

**Abstract**

Laparoscopic rectal surgery has demonstrated its superiority over the open approach, however it still has some technical limitations that lead to the development of robotic platforms. Nevertheless the literature on this topic is rapidly expanding there is still no consensus about benefits of robotic rectal cancer surgery over the laparoscopic one. For this reason a review of all the literature examining robotic surgery for rectal cancer was performed. Two reviewers independently conducted a search of electronic databases (PubMed and Embase) using the key words “rectum”, “rectal”, “cancer”, “laparoscopy”, “robot”. After the initial screen of 266 articles, 43 papers were selected for review. A total of 3013 patients were included in the review. The most commonly performed intervention was low anterior resection (1450 patients, 48.1%), followed by anterior resections (997 patients, 33%), ultra-low anterior resections (393 patients, 13%) and abdominoperineal resections (173 patients, 5.7%). Robotic rectal surgery seems to offer potential advantages especially in low anterior resections with lower conversions rates and better preservation of the autonomic function. Quality of mesorectum and status of and circumferential resection margins are similar to those obtained with conventional laparoscopy even if robotic rectal surgery is undoubtedly associated with longer operative times. This review demonstrated that robotic rectal surgery is both safe and feasible but there is no evidence of its superiority over laparoscopy in terms of postoperative, clinical outcomes and incidence of complications. In conclusion robotic rectal surgery seems to overcome some of technical limitations of conventional laparoscopic surgery especially for tumors requiring low and ultra-low anterior resections but this technical improvement seems not to provide, until now, any significant clinical advantages to the patients.

**Key words:** Robotic surgery; Robotic rectal surgery; DaVinci rectal surgery; Robotic rectal cancer; Robotics for rectal cancer; Robotic rectal resection

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Laparoscopic rectal surgery has progressively expanded. However it has some technical limitations. The need to overcome these limitations leads to the development of robotic platforms. Although the positive feedback is by the surgeons, there is still no evidence in literature about the superiority of robotic rectal surgery when compared to traditional laparoscopy.

Staderini F, Caterina F, Alessio M, Benedetta B, Etleva Q, Giuliano P, Giacomo T, Beatrice M, Gabriele L, Giuseppe M, Andrea B, Siro B, Giuliano P, Fabio C. Robotic rectal surgery: State of the art. *World J Gastrointest Oncol* 2016; In press

**INTRODUCTION**

Laparoscopic colorectal surgery has progressively expanded since a number of randomized controlled trials (RCTs)[1-3], review articles[4,5], meta-analysis[6] and case series[7] have demonstrated its better postoperative outcomes when compared to open surgery. However, laparoscopic surgery has some technical limitations such as poor ergonomics, 2-dimension view, coning and fulcrum effect, that may influence surgery in narrow anatomical fields such as in the pelvis during rectal surgery. The need to overcome these limitations leads to the development of robotic platforms. The da Vinci robotic surgical system is the only totally robotic platform available. After approval by FDA in 2000, its use progressively spreaded as demonstrated by the increasing number of publications. Three-D high definition vision, wrist-like movement of instruments (endowristTM), stable camera holding, motion filter for tremor-free surgery and improved ergonomics for the surgeon are the advantages of the robotic system that may make rectal surgery more affordable and theoretically should provide better outcomes for the patient. Although the positive feedback is by the surgeons, there is still no evidence in literature about the superiority of robotic rectal surgery when compared to traditional laparoscopy. The aim of this study was to review the rapidly expanding literature in order to focus on the current state and assess any benefits of robotic rectal cancer surgery.

**RESEARCH AND LITERATURE**

A review of the literature examining robotic surgery for rectal cancer during the period from 2000 to 2015 was performed. Two reviewers independently conducted a search of electronic databases (PubMed and Embase) using the key words “rectum”, “rectal”, “cancer”, “laparoscopy”, “robot”. The reference lists provided by the identified articles were additionally hand-searched to prevent article loss by the search strategy. This method of cross-references was continued until no further relevant publications were identified. The last search was performed on December 2015. Inclusion criteria were prospective, retrospective, randomized, comparative studies about robotic rectal surgery for cancer including anterior resections, low anterior resections, ultralow anterior resections, abdominoperineal resections, proctectomies, proctocolectomies. Exclusion criteria were: abstracts, letters, editorials, technical notes, expert opinions, reviews, meta-analysis, studies reporting benign pathologies, studies in which the outcomes and parameters of patients were not clearly reported, studies in which it was not possible to extract the appropriate data from the published results, overlap between authors and centers in the published literature, non-English language papers.

The literature search yielded 266 papers, the process is listed in Figure 1. After the 1st filtering, the remaining 60 studies were 33 comparative, 26 case series, and 1 RCT. Then 17 studies were excluded due to duplicated data. They were 7 comparative and 9 case series. After this process a total of 43 papers, 27 comparative including only 1 RCT and 16 case series were included and reviewed.

**STUDIES OVERVIEW**

The number of publications about robotic rectal surgery for cancer has been constantly increasing. Among the papers we included there was only 1 paper per year published in 2006, 2007, 2008, 3 papers in 2009, 2 in 2010, 5 per year in 2011 and 2012, 10 in 2013 and 15 in 2014. With regard to the nationality of the 1st author there were 16 studies in the South Korea (37.2%), 11 in the United States (25.5%), 4 in Italy (9.3%), 2 in Turkey (4.6%), 2 in the Singapore (4.6%), 1 in Japan (2.3%), 1 in Denmark (2.3%), 1 in Spain (2.3%), 1 in Romania (2.3%), 1 in Brazil (2.3%), 1 in Canada (2.3%), 1 in Taiwan (2.3%), 1 in China (2.3%) (Table 1).

***Surgical technique***

A total of 3013 robotic operations were performed. 16 studies[10,12,14,16,17,22,23,25,27,28,37,38,40-42,48] (1257 patients) reported a totally robotic procedure which was carried out with either a single[10,16,17,22,23,25,27,28,37,38,40-42,48] or a double docking[12,28] technique. In 22 studies[8,13,15,18,20,21,25,26,30-34,36,39,43-47,49,50] (1384 patients) an hybrid robotic technique was performed: the inferior mesenteric vessels ligation and splenic flexure mobilization were performed laparoscopically whereas pelvic dissection and total mesorectal excision were performed robotically. In 5 studies[9,11,19,29,35] (372 patients) the robotic technique was not specified. Laparoscopic procedures described in the 27 comparative studies[8-33] were performed in the same manner as robotic surgery using laparoscopic instruments (Table 1).

***Demographics and preoperative data***

Most of patients were male (1911, 63%), the mean age was 58, the mean BMI was 26.6. Nine hundred-eight patients (20%) underwent a neoadjuvant chemotherapy, 71 (2.3%) a neoadjuvant chemo-radiotherapy and 8 (0.2%) radiotherapy only. With regard to the type of operation, 1450 (48.1%) were low anterior resections (LAR), 997 (33%) were anterior resections (AR), 393 (13%) ultra-low anterior resections (ULAR) and 173 (5.7%) abdominoperineal resections (APR). In the studies where the type of operation was not specified and where it was stated that a TME was performed[27,29,41] we assumed that all operations were low anterior resections (LAR) (Table 2)

***Operative data***

The mean robotic operative time ranged from 202 min[31] to 485.8 min[17]. For the 1345 laparoscopic patients in the selected comparative studies the mean operative time ranged from 158.1[30] to 374.3 min[17]. This difference was statistically significant in 12 comparative studies[10,14,17,18-24,27,28,30] with a longer time for robotic surgery. Levic *et al*[9] were the only authors that reported a longer laparoscopic operative time (*P* = 0.055), but all interventions were performed with a single port technique (Table 3).

 The estimated blood loss (EBL) was not reported in 14 studies. The mean value ranged from 17 mL[36] to 280 mL[14] with the robotic approach and from 59.2[18] to 271.4[15] in the laparoscopic group. Among 16 comparative studies[8-10,12-15,17,19-21,23,24,29,31,33] that evaluated the EBL only Kang *et al*[23] and Erguner *et al*[21] reported a significantly lower EBL with the robotic approach when compared to the laparoscopic one.

 Thirty seven studies reported the conversion rate to open surgery. Three[8,22,31] out of 22 comparative studies[8-15,17,19-23-25,28-33] showed asignificantly lower conversion rate in the robotic series when compared to laparoscopy. The difference in overall conversion rate reported by Ielpo *et al*[14] was not statistically significant. However, when data were analyzed according to the tumor location (upper, mid, lower rectum), the conversion rates between robotic and laparoscopic procedures for lower rectal cancers were respectively 1.8% and 9.2% (*P* = 0.04).

 The rate of patients that underwent a protective ileostomy creation ranged from 0%[30] to 100%[10] both in the robotic and laparoscopic group. The difference in protective ileostomy creation was statistically significant in 5 studies. Kuo *et al*[17] reported a lower rate in the robotic versus the laparoscopic group whereas Saklani *et al*[19], Erguner *et al*[21], Park *et al*[25], Baek *et al*[29] showed a lower rate in the laparoscopic versus the robotic group.

***Postoperative data***

The mean postoperative day to first flatus ranged from 1.9[48] to 3.2[30] d in the robotic cases and from 2.4[23] to 3.4[17] in the laparoscopic ones. No statistically significant difference between robotic and laparoscopic cases was reported in any of the articles reviewed (Table 4).

 The day of first postoperative liquid diet was available in 11 studies[6,22,27,29,34,36,43,45,47,48,50] ranging from 1[16] to 3.9[45] d in the robotic cases. Only two[22,29] comparative studies reported the first postoperative liquid diet in their robotic and laparoscopic series, in one[22] of these the difference was statistically significant in favour of robotic surgery (3 d *vs* 5 d, *P* = 0.005).

 The day of first postoperative solid diet was available in 11 studies[8,10,13,17,19,23-25,30,34,37] ranging from 2.58[10] to 7.5[18] din the robotic cases and from 2.48[10] to 7.7[18] d in laparoscopic cases. Among 9 comparative studies[8,10,13,17,19,23-25,30] only Kang *et al*[23]reported a significant earlier oral intake in the robotic group (4.5 d *vs* 5.2 d. *P* = 0.004) when compared to the laparoscopic one.

 The mean length of hospital stay ranged from 4.5[33] to 14.2[17] and from 3.6 [33] to 15.1[17] d after robotic and laparoscopic surgery respectively. Among 8 comparative studies, Tam *et al*[15], Levic *et al*[9] and Park *et al*[30] reported a shorter length of stay in their laparoscopic series whereas 5[8,22-24,32] studies reported a significant shorter length of stay after robotic surgery.

 No statistically significant differences in the overall 30 d mortality between the robotic and laparoscopic approach was found among 15 comparative studies[8-11,13,14,19,20-24,29-31] (0.10% and 0.45% respectively).

 Twenty-three studies reported the reintervention rate. In the robotic series it ranged from 0%[8,22,32,33,42,48] to 15%[20] whereas it ranged from 0%[32,33] to 15.7%[11] after laparoscopic surgery. The most common cause of reintervention was anastomotic leak in both the robotic and laparoscopic groups. No statistically significant differences were found in any of the 12 comparative studies[11-15,20-24,32,33].

 The overall complication rate in the robotic and laparoscopic groups was 24.5% and 27.7% respectively. No significant differences in this parameter were reported between the robotic and laparoscopic series[8-11,13-15,19-25,28-33]. The most frequent complication in both the robotic and laparoscopic cases was anastomotic leak followed by bowel obstruction and urinary complications (Table 5). Thirteen studies[10,18,19,22-24,26,31,37,38,40,44,45] reported urinary and sexual dysfunction after rectal surgery, 9 of these were comparative. Park *et al*[18] reported an earlier and significant restoration of erectile function after robotic surgery when compared to the laparoscopic one. Kim *et al*[26] observed an earlier recover of urinary function after robotic intervention within six months from the operation (*P* = 0.001). After 6 months the difference was no more statistically significant.

 Table 6 shows the studies which classified complications according to the Clavien Dindo Scoring System. Clavien-Dindo 1 and 2 were the most frequent complications in both groups (13.8% robotic *vs* 12.4% laparoscopic).

***Oncological outcome***

The mean number of harvested nodes ranged from 10[14] to 20.6[48] and from 9[14] to 21[10] in the robotic and laparoscopic cases respectively. Three of 22 comparatives[8-10,11-15,17,19-25,28-33] studies reported a statistically significant difference in the number of harvested nodes between the robotic and laparoscopic approach: Levic *et al*[9] and D’Annibale *et al*[22] showed an higher number of examined nodes after robotic surgery whereas Yoo *et al*[10] showed an higher number of examined nodes after laparoscopic surgery (Table 7).

 The mean length of distal resection margins after robotic rectal surgery was available in 20 studies[8-10,13,15-17,19,21-38,40,41,43,45,48,50]. It ranged from 13.3 mm[10] to 460 mm[15]. Tumor involvement rate of distal margins was available 21 studies[8,9,11,12,15,17,20,21,23,25,26,28-30,34,36,37,39,46,48,50] and ranged from 0%[8,15,17,20,21,25,26,28-30,34,36,37,48,50] to 2.6%[39] of patients. An involvement of distal resection margin was found in 6 (0.47%) out of 1257 patients operated on with the robotic technique.

 The mean length of distal resection margins after laparoscopic rectal surgery was available in 19[8-10,13,15,17,19,21-26,28-33] studies. It ranged from 13 mm[25] to 510 mm[15]. The involvement of distal margins was available in 14 studies[8,9,11,12,15,17,20,21,23,25,26,28-30] and ranged from 0%[8,9,11,12,15,21,23,25,26,28-30] to 5%[15] of patients. A distal margin positivity was reported in 3 (0.3%) out of 857 patients. Among the 19 comparative[8-10,13,15,17,19,21-26,28-33] studies only Kim *et al*[24]reported a longer distal margin in the robotic than in the laparoscopic group (*P* = 0.04). No significant difference in distal margins tumor involvement was reported when the robotic and laparoscopic approaches were compared.

 Mean circumferential resection margins (CRM) after robotic rectal surgery were reported in 9 studies[9,13,17,21,25,30,43,44,47] ranging from 1.8 mm[43] to 11 mm [44]. CRM tumor involvement was available in 32 studies[8,10-12,14-17,19,20,22-30,35-37,39,40,42,44-50] and ranged from 0%[15,16,20,22,3642,444649,50] to 11.1%[17] of patients with a 2.94 overall rate (76 out of 2583 patients).

Mean CRM after laparoscopic rectal surgery were reported in 6[9,13,17,21,25,30] comparative studies. It ranged from 4 mm[21] to 8.2 mm[30]. CRM involvement was reported in 17 studies[8,10-12,14,15,17,19,20,22-26,28-30] and occurred in 51 out of 1158 patients (4.4%) Where the 2 procedures where compared only D’Annibale[22] observed a significantly greater number of patients with positive CRM in the laparoscopic series when compared with the robotic one.

 Only in 11 papers[9,11,13,20,21,26,32,34,36,41,44] reported the quality of mesorectum. Complete mesorectum excision ranged from 100%[11,36] to 60%[9] in the robotic series and from 100%[11] to 40.6%[9] after laparoscopy. Total mesorectal excision was achieved in 83.62% of robotic cases *vs* 77.22% of laparoscopic ones. None of the 7 comparative studies showed a significant difference in the quality of mesorectum between the 2 procedures.

***Short-term oncologic outcomes***

Only 11 authors[8,9,10,16,19,25,28,31,38,42,47] reported short term oncologic outcomes (Table 8). The main drawback is the heterogeneity of the length of follow up ranging from 1 month[9,42] to 80 months[ 8] making results difficult to compare. The disease free survival in the laparoscopic group ranged from 75%[10] to 89.2%[31] with local recurrence ranging from 0%[9,42] to 16.6%[8] and an overall survival ranging from 88.5%[10] to 98%[24]. The disease free survival in the robotic group ranged from 70.4%[16] to 100%[31,42] with local recurrence ranging from 0%[9,31,42] to 12.8%[10] and an overall survival ranging from 85%[16] to100%[42].

**CONCLUSION AND DISCUSSION**

Robotic rectal surgery is constantly increasing over the years. Previous reviews have already demonstrated its safety and feasibility[51-53], although there are not published studies demonstrating its superiority over the laparoscopic approach mainly due to the lack of randomized control trials. This lack of evidence about the effectiveness of robotic rectal surgery is in contrast with the overall opinion of surgeons that report an easier surgical approach especially to narrow and difficult anatomic spaces such as the pelvis. Several authors[52-54] reported 3D high definition vision, wrist-like movement of instruments (endowristTM), stable camera holding, motion filter for tremor-free surgery and improved ergonomics as major improvements in rectal surgery but it seems that these technical benefits have not reflected better clinical outcomes yet. This review aimed to analyze robotic rectal surgery from the first report to nowadays in order to focus on the current state and assess any benefits of robotic rectal surgery and its evolution through the years.

A well-established finding of this review is the longer operative time of robotic surgery when compared to the laparoscopic one. This is most likely due not to longer dissection but to non-surgical technical time. In fact in the totally robotic approach the docking and undocking has to be performed twice and in the hybrid approach there is the need to switch from laparoscopy to robot. A totally robotic technique without undocking is feasible, but this approach is technically much more difficult and as a consequence, a longer operative time is needed[10,12,14,16,17,22-24,27,28,37,38,40-42,48]. Traditionally, longer operative time is related with increased morbidity, most likely related to the difficulty of the operation[53]. However prolonged times in robotic surgery are not associated with an increased complication rate as demonstrated by this review and previously published review and meta-analysis[55].

 In our review 2[21,23] out of 16 comparative studies reported a significantly lower estimated blood loss after robotic rectal surgery confirming that there is still no evidence that robotic rectal surgery for cancer may be associated with a lower intraoperative blood loss.

 As regards convertion rates to open surgery, 3[8,22,31] out of 22 comparative studies reported significant lower complication rates in robotic patients. Many authors associated these results to better visualization, 3D view, endowristTM technology and stable camera holding resulting in an easier dissection in narrow anatomical fields such as the pelvis[56]. Even the results reported by Ielpo *et al*[14] suggest that the robotic approach has lower conversion rates when the tumor location requests a low anterior resection and as a consequence, when the operations is technically more challenging. Since converted cases are associated to greater morbidity and tumor recurrence[57], robotic surgery could provide better oncologic long term results as well as a decreased perioperative morbidity.

 The difference in protective ileostomy creation observed in this review can be related to several factors: the surgeon’s habit, the tumor location, the surgeon’s learning curve. Moreover, a trend toward an increasing stoma creation after robotic surgery could have been verified because of the initial worries about the new technique. On the bases of our findings the robotic approach seems associated with a higher rate of protective stoma creation.

 One of the main benefits of minimally invasive surgery is the early recover. In this review we were unable to draw definitive results about any benefit of the robotic technique over conventional laparoscopy. Length of hospital stay, day of 1st flatus, 1st solid diet and 1st liquid diet were substantially similar in both the robotic and laparoscopic series even if some authors reported some advantages for either the robotic or the laparoscopic technique[8,9,15,22-24,30,32].

 Anastomotic leak is the most severe surgical complication in rectal surgery. Well known risk factors for anastomotic leak are represented by cancers located less than 6 cm from anal verge, neoadjuvant radio-chemotherapy, obesity and intraoperative blood transfusions[58-63]. In this review the overall anastomotic leak rates in the robotic and laparoscopic series were similar (7.3% *vs* 7.6%) with no comparative study reporting any significant difference between the 2 types of procedure. All together these results demonstrate that robotic surgery does not reduce the anastomotic leak rate. Nevertheless results of comparative studies are contradictory since 9[11,15,19,20-22,23,25,30] of these reported less anastomotic leaks in the robotic group and 9[8-10,14,17,24,28,29,31] in the laparoscopic one, but none of these results was significant. Looking at intraoperative complications, only Levic *et al*[9] reported a significant, higher rate in the robotic patients (4.48% *vs* 0%). However it must be considered that in this study there were more obese patients in the robotic group and all robotic and laparoscopic operations were performed in 2 different hospitals.

 The number of harvested and examined lymph nodes is pivotal in the postoperative tumor staging whose accuracy increases with the number of nodes retrieved within the surgical specimen. The robotic platform with its 3D high definition vision and wrist-like movement of instruments should improve the lymph nodes retrieving. Nevertheless, the difference between the mean harvested lymph nodes in the robotic and laparoscopic series was not substantial in our review (15.1 *vs* 15.7 respectively) and only 2 authors[9,10] reported a significant higher number of retrieved lymph nodes in the robotic group.

 The length of tumor involvement of both the distal and circumferential resection margins is considered an important parameter in evaluating the treatment of rectal cancer. Findings from the present review seems to determinate the lack of any advantages of robotic surgery over the laparoscopic approach. This issue might be explained by the likely surgeon’s trend to prefer robotic approach in more advanced and distal tumors because of the theoretical superiority of this technique in pelvic dissection. In this review indeed 7 authors[10,11,15,20,22,25,31] reported a significant lower distance of the tumor from anal verge when the robotic approach was compared with the laparoscopic one. Two comparative studies[13,22] reported even a significant wider CRM in their robotic series when compared to the laparoscopic ones. However a possible bias in the evaluation of this parameter is the non-uniform recording of data: some authors report median values, others the mean values making data not comparable. Even definition of circumferential resection margin is still not clear as it is currently considered as positive as positive if < 1 mm[8,11,14,19,24,25,30,35,64] by some authors and < 2 mm[10,12,15-17,20,22,23,26-29,36,37,39,40,42,44-50] by others.

 Thanks to its technical characteristics the robot platform should help in performing total and complete mesorectal excision that is an important target in rectal surgery since it potentially reflects the radicality of the operation. Unfortunately even if this is a major parameter in evaluating the radicality of the intervention, only 11 out of 43 studies in this review have addressed this important parameter. On the basis of our results any superiority of robotic mesorectal excision over the laparoscopic one cannot be demonstrated.

 Robotic surgery may help in the identification and preservation of autonomic nerves due to high definition 3D image. Common sites of potential nerve damage are the superior hypogastric plexus, leading to ejaculation dysfunction in males and impaired lubrification in females, and the pelvic splanchnic nerve/pelvic plexus leading to erectile dysfunction in men. According to results of the CLASSIC trial[59] the risk of an autonomic injury with sexual dysfunction in males is significantly higher in laparoscopic surgery when compared to the open approach. The perceived advantages of robotic surgery may translate to decreased incidence of urinary dysfunction and erectile dysfunction in males. Although some preliminary results suggested that robotic assisted rectal surgery is superior to conventional laparoscopic surgery in preventing sexual or urinary dysfunction[63,64], we cannot provide definitive results since only few studies addressed this issue with high heterogeneity in the scores systems used for the analysis. Furthermore not all the patients in the studies agreed in answering questionnaires and this could lead to a possible type II error. Some authors[26,18] reported an earlier recovery of erectile, sexual desire and urinary function when the robotic group was compared with the laparoscopic one but they did not report any difference in long-term follow-up.

 In conclusion, results from the present review show that robotic surgery is as feasible and safe as conventional laparoscopy in the treatment of rectal cancer, with the only drawback of longer operative time. The magnified view, the improved ergonomics and dexterity might improve the diffusion of minimally invasive approach in the treatment of rectal cancer. Potential clinical benefits of the robotic technique must be demonstrated, if any, only by RCTs.

**REFERENCES**

1 **Guillou PJ**, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet* 2005; **365**: 1718-1726 [PMID: 15894098 DOI: 10.1016/S0140-6736(05)66545-2]

2 **Lacy AM**, García-Valdecasas JC, Delgado S, Castells A, Taurá P, Piqué JM, Visa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. *Lancet* 2002; **359**: 2224-2229 [PMID: 12103285 DOI: 10.1016/S0140-6736(02)09290-5]

3 **Veldkamp R**, Kuhry E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ, Haglind E, Påhlman L, Cuesta MA, Msika S, Morino M, Lacy AM. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. *Lancet Oncol* 2005; **6**: 477-484 [PMID: 15992696 DOI: 10.1016/S1470-2045(05)70221-7]

4 **Kuhry E**, Schwenk WF, Gaupset R, Romild U, Bonjer HJ. Long-term results of laparoscopic colorectal cancer resection. *Cochrane Database Syst Rev* 2008; **(2)**: CD003432 [PMID: 18425886]

5 **McKay GD**, Morgan MJ, Wong SK, Gatenby AH, Fulham SB, Ahmed KW, Toh JW, Hanna M, Hitos K. Improved short-term outcomes of laparoscopic versus open resection for colon and rectal cancer in an area health service: a multicenter study. *Dis Colon Rectum* 2012; **55**: 42-50 [PMID: 22156866 DOI: 10.1097/DCR.0b013e318239341f]

6 **Abraham NS**, Young JM, Solomon MJ. Meta-analysis of short-term outcomes after laparoscopic resection for colorectal cancer. *Br J Surg* 2004; **91**: 1111-1124 [PMID: 15449261 DOI: 10.1002/bjs.4640]

7 **Cianchi F**, Cortesini C, Trallori G, Messerini L, Novelli L, Comin CE, Qirici E, Bonanomi A, Macrì G, Badii B, Kokomani A, Perigli G. Adequacy of lymphadenectomy in laparoscopic colorectal cancer surgery: a single-centre, retrospective study. *Surg Laparosc Endosc Percutan Tech* 2012; **22**: 33-37 [PMID: 22318057 DOI: 10.1097/SLE.0b013e31824332dc]

8 **Park EJ**, Cho MS, Baek SJ, Hur H, Min BS, Baik SH, Lee KY, Kim NK. Long-term oncologic outcomes of robotic low anterior resection for rectal cancer: a comparative study with laparoscopic surgery. *Ann Surg* 2015; **261**: 129-137 [PMID: 24662411 DOI: 10.1097/SLA.0000000000000613]

9 **Levic K**, Donatsky AM, Bulut O, Rosenberg J. A Comparative Study of Single-Port Laparoscopic Surgery Versus Robotic-Assisted Laparoscopic Surgery for Rectal Cancer. *Surg Innov* 2015; **22**: 368-375 [PMID: 25377216 DOI: 10.1177/1553350614556367]

10 **Yoo BE**, Cho JS, Shin JW, Lee DW, Kwak JM, Kim J, Kim SH. Robotic versus laparoscopic intersphincteric resection for low rectal cancer: comparison of the operative, oncological, and functional outcomes. *Ann Surg Oncol* 2015; **22**: 1219-1225 [PMID: 25326398 DOI: 10.1245/s10434-014-4177-5]

11 **Koh FH**, Tan KK, Lieske B, Tsang ML, Tsang CB, Koh DC. Endowrist versus wrist: a case-controlled study comparing robotic versus hand-assisted laparoscopic surgery for rectal cancer. *Surg Laparosc Endosc Percutan Tech* 2014; **24**: 452-456 [PMID: 25275815 DOI: 10.1097/SLE.0b013e318290158d]

12 **Melich G**, Hong YK, Kim J, Hur H, Baik SH, Kim NK, Sender Liberman A, Min BS. Simultaneous development of laparoscopy and robotics provides acceptable perioperative outcomes and shows robotics to have a faster learning curve and to be overall faster in rectal cancer surgery: analysis of novice MIS surgeon learning curves. *Surg Endosc* 2015; **29**: 558-568 [PMID: 25030474 DOI: 10.1007/s00464-014-3698-0]

13 **Barnajian M**, Pettet D, Kazi E, Foppa C, Bergamaschi R. Quality of total mesorectal excision and depth of circumferential resection margin in rectal cancer: a matched comparison of the first 20 robotic cases. *Colorectal Dis* 2014; **16**: 603-609 [PMID: 24750995 DOI: 10.1111/codi.12634]

14 **Ielpo B**, Caruso R, Quijano Y, Duran H, Diaz E, Fabra I, Oliva C, Olivares S, Ferri V, Ceron R, Plaza C, Vicente E. Robotic versus laparoscopic rectal resection: is there any real difference? A comparative single center study. *Int J Med Robot* 2014; **10**: 300-305 [PMID: 24692203 DOI: 10.1002/rcs.1583]

15 **Tam MS**, Abbass M, Abbas MA. Robotic-laparoscopic rectal cancer excision versus traditional laparoscopy. *JSLS* 2014; **18**: [PMID: 25392653 DOI: 10.4293/JSLS.2014.00020]

16 **Ghezzi TL**, Luca F, Valvo M, Corleta OC, Zuccaro M, Cenciarelli S, Biffi R. Robotic versus open total mesorectal excision for rectal cancer: comparative study of short and long-term outcomes. *Eur J Surg Oncol* 2014; **40**: 1072-1079 [PMID: 24646748 DOI: 10.1016/j.ejso.2014.02.235]

17 **Kuo LJ**, Lin YK, Chang CC, Tai CJ, Chiou JF, Chang YJ. Clinical outcomes of robot-assisted intersphincteric resection for low rectal cancer: comparison with conventional laparoscopy and multifactorial analysis of the learning curve for robotic surgery. *Int J Colorectal Dis* 2014; **29**: 555-562 [PMID: 24562546 DOI: 10.1007/s00384-014-1841-y]

18 **Park SY**, Choi GS, Park JS, Kim HJ, Ryuk JP, Yun SH. Urinary and erectile function in men after total mesorectal excision by laparoscopic or robot-assisted methods for the treatment of rectal cancer: a case-matched comparison. *World J Surg* 2014; **38**: 1834-1842 [PMID: 24366278 DOI: 10.1007/s00268-013-2419-5]

19 **Saklani AP**, Lim DR, Hur H, Min BS, Baik SH, Lee KY, Kim NK. Robotic versus laparoscopic surgery for mid-low rectal cancer after neoadjuvant chemoradiation therapy: comparison of oncologic outcomes. *Int J Colorectal Dis* 2013; **28**: 1689-1698 [PMID: 23948968 DOI: 10.1007/s00384-013-1756-z]

20 **Fernandez R**, Anaya DA, Li LT, Orcutt ST, Balentine CJ, Awad SA, Berger DH, Albo DA, Artinyan A. Laparoscopic versus robotic rectal resection for rectal cancer in a veteran population. *Am J Surg* 2013; **206**: 509-517 [PMID: 23809672 DOI: 10.1016/j.amjsurg.2013.01.036]

21 **Erguner I**, Aytac E, Boler DE, Atalar B, Baca B, Karahasanoglu T, Hamzaoglu I, Uras C. What have we gained by performing robotic rectal resection? Evaluation of 64 consecutive patients who underwent laparoscopic or robotic low anterior resection for rectal adenocarcinoma. *Surg Laparosc Endosc Percutan Tech* 2013; **23**: 316-319 [PMID: 23752000 DOI: 10.1097/SLE.0b013e31828e3697]

22 **D'Annibale A**, Pernazza G, Monsellato I, Pende V, Lucandri G, Mazzocchi P, Alfano G. Total mesorectal excision: a comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. *Surg Endosc* 2013; **27**: 1887-1895 [PMID: 23292566 DOI: 10.1007/s00464-012-2731-4]

23 **Kang J**, Yoon KJ, Min BS, Hur H, Baik SH, Kim NK, Lee KY. The impact of robotic surgery for mid and low rectal cancer: a case-matched analysis of a 3-arm comparison--open, laparoscopic, and robotic surgery. *Ann Surg* 2013; **257**: 95-101 [PMID: 23059496 DOI: 10.1097/SLA.0b013e3182686bbd]

24 **Park SY**, Choi GS, Park JS, Kim HJ, Ryuk JP. Short-term clinical outcome of robot-assisted intersphincteric resection for low rectal cancer: a retrospective comparison with conventional laparoscopy. *Surg Endosc* 2013; **27**: 48-55 [PMID: 22752275 DOI: 10.1007/s00464-012-2405-2]

25 **Kim YW**, Lee HM, Kim NK, Min BS, Lee KY. The learning curve for robot-assisted total mesorectal excision for rectal cancer. *Surg Laparosc Endosc Percutan Tech* 2012; **22**: 400-405 [PMID: 23047381 DOI: 10.1097/SLE.0b013e3182622c2d]

26 **Kim JY**, Kim NK, Lee KY, Hur H, Min BS, Kim JH. A comparative study of voiding and sexual function after total mesorectal excision with autonomic nerve preservation for rectal cancer: laparoscopic versus robotic surgery. *Ann Surg Oncol* 2012; **19**: 2485-2493 [PMID: 22434245 DOI: 10.1245/s10434-012-2262-1]

27 **Bertani E**, Chiappa A, Biffi R, Bianchi PP, Radice D, Branchi V, Cenderelli E, Vetrano I, Cenciarelli S, Andreoni B. Assessing appropriateness for elective colorectal cancer surgery: clinical, oncological, and quality-of-life short-term outcomes employing different treatment approaches. *Int J Colorectal Dis* 2011; **26**: 1317-1327 [PMID: 21750927 DOI: 10.1007/s00384-011-1270-0]

28 **Kwak JM**, Kim SH, Kim J, Son DN, Baek SJ, Cho JS. Robotic vs laparoscopic resection of rectal cancer: short-term outcomes of a case-control study. *Dis Colon Rectum* 2011; **54**: 151-156 [PMID: 21228661 DOI: 10.1007/DCR.0b013e3181fec4fd]

29 **Baek JH**, Pastor C, Pigazzi A. Robotic and laparoscopic total mesorectal excision for rectal cancer: a case-matched study. *Surg Endosc* 2011; **25**: 521-525 [PMID: 20607559 DOI: 10.1007/s00464-010-1204-x]

30 **Park JS**, Choi GS, Lim KH, Jang YS, Jun SH. S052: a comparison of robot-assisted, laparoscopic, and open surgery in the treatment of rectal cancer. *Surg Endosc* 2011; **25**: 240-248 [PMID: 20552367 DOI: 10.1007/s00464-010-1166-z]

31 **Patriti A**, Ceccarelli G, Bartoli A, Spaziani A, Biancafarina A, Casciola L. Short- and medium-term outcome of robot-assisted and traditional laparoscopic rectal resection. *JSLS* 2009; **13**: 176-183 [PMID: 19660212]

32 **Baik SH**, Ko YT, Kang CM, Lee WJ, Kim NK, Sohn SK, Chi HS, Cho CH. Robotic tumor-specific mesorectal excision of rectal cancer: short-term outcome of a pilot randomized trial. *Surg Endosc* 2008; **22**: 1601-1608 [PMID: 18270772 DOI: 10.1007/s00464-008-9752-z]

33 **Pigazzi A**, Ellenhorn JD, Ballantyne GH, Paz IB. Robotic-assisted laparoscopic low anterior resection with total mesorectal excision for rectal cancer. *Surg Endosc* 2006; **20**: 1521-1525 [PMID: 16897284 DOI: 10.1007/s00464-005-0855-5]

34 **Parisi A**, Desiderio J, Trastulli S, Cirocchi R, Ricci F, Farinacci F, Mangia A, Boselli C, Noya G, Filippini A, D'Andrea V, Santoro A. Robotic rectal resection for cancer: a prospective cohort study to analyze surgical, clinical and oncological outcomes. *Int J Surg* 2014; **12**: 1456-1461 [PMID: 25463766 DOI: 10.1016/j.ijsu.2014.11.012]

35 **Baek SJ**, Kim CH, Cho MS, Bae SU, Hur H, Min BS, Baik SH, Lee KY, Kim NK. Robotic surgery for rectal cancer can overcome difficulties associated with pelvic anatomy. *Surg Endosc* 2015; **29**: 1419-1424 [PMID: 25159651 DOI: 10.1007/s00464-014-3818-x]

36 **Shiomi A**, Kinugasa Y, Yamaguchi T, Tomioka H, Kagawa H. Robot-assisted rectal cancer surgery: short-term outcomes for 113 consecutive patients. *Int J Colorectal Dis* 2014; **29**: 1105-1111 [PMID: 24942499 DOI: 10.1007/s00384-014-1921-z]

37 **Kim IK**, Kang J, Park YA, Kim NK, Sohn SK, Lee KY. Is prior laparoscopy experience required for adaptation to robotic rectal surgery?: Feasibility of one-step transition from open to robotic surgery. *Int J Colorectal Dis* 2014; **29**: 693-699 [PMID: 24770702 DOI: 10.1007/s00384-014-1858-2]

38 **Stănciulea O**, Eftimie M, David L, Tomulescu V, Vasilescu C, Popescu I. Robotic surgery for rectal cancer: a single center experience of 100 consecutive cases. *Chirurgia (Bucur)* 2013; **108**: 143-151 [PMID: 23618561]

39 **Zawadzki M**, Velchuru VR, Albalawi SA, Park JJ, Marecik S, Prasad LM. Is hybrid robotic laparoscopic assistance the ideal approach for restorative rectal cancer dissection? *Colorectal Dis* 2013; **15**: 1026-1032 [PMID: 23528255 DOI: 10.1111/codi.12209]

40 **Sng KK**, Hara M, Shin JW, Yoo BE, Yang KS, Kim SH. The multiphasic learning curve for robot-assisted rectal surgery. *Surg Endosc* 2013; **27**: 3297-3307 [PMID: 23508818 DOI: 10.1007/s00464-013-2909-4]

41 **Du XH**, Shen D, Li R, Li SY, Ning N, Zhao YS, Zou ZY, Liu N. Robotic anterior resection of rectal cancer: technique and early outcome. *Chin Med J (Engl)* 2013; **126**: 51-54 [PMID: 23286477]

42 **Alimoglu O**, Atak I, Kilic A, Caliskan M. Robot-assisted laparoscopic abdominoperineal resection for low rectal cancer. *Int J Med Robot* 2012; **8**: 371-374 [PMID: 22473676 DOI: 10.1002/rcs.1432]

43 **Akmal Y**, Baek JH, McKenzie S, Garcia-Aguilar J, Pigazzi A. Robot-assisted total mesorectal excision: is there a learning curve? *Surg Endosc* 2012; **26**: 2471-2476 [PMID: 22437950]

44 **Park IJ**, You YN, Schlette E, Nguyen S, Skibber JM, Rodriguez-Bigas MA, Chang GJ. Reverse-hybrid robotic mesorectal excision for rectal cancer. *Dis Colon Rectum* 2012; **55**: 228-233 [PMID: 22228169 DOI: 10.1097/DCR.0b013e31823c0bd2]

45 **Kang J**, Min BS, Park YA, Hur H, Baik SH, Kim NK, Sohn SK, Lee KY. Risk factor analysis of postoperative complications after robotic rectal cancer surgery. *World J Surg* 2011; **35**: 2555-2562 [PMID: 21913134 DOI: 10.1007/s00268-011-1270-9]

46 **deSouza AL**, Prasad LM, Marecik SJ, Blumetti J, Park JJ, Zimmern A, Abcarian H. Total mesorectal excision for rectal cancer: the potential advantage of robotic assistance. *Dis Colon Rectum* 2010; **53**: 1611-1617 [PMID: 21178854 DOI: 10.1007/DCR.0b013e3181f22f1f]

47 **Pigazzi A**, Luca F, Patriti A, Valvo M, Ceccarelli G, Casciola L, Biffi R, Garcia-Aguilar J, Baek JH. Multicentric study on robotic tumor-specific mesorectal excision for the treatment of rectal cancer. *Ann Surg Oncol* 2010; **17**: 1614-1620 [PMID: 20087780 DOI: 10.1245/s10434-010-0909-3]

48 **Choi DJ**, Kim SH, Lee PJ, Kim J, Woo SU. Single-stage totally robotic dissection for rectal cancer surgery: technique and short-term outcome in 50 consecutive patients. *Dis Colon Rectum* 2009; **52**: 1824-1830 [PMID: 19966627 DOI: 10.1007/DCR.0b013e3181b13536]

49 **Ng KH**, Lim YK, Ho KS, Ooi BS, Eu KW. Robotic-assisted surgery for low rectal dissection: from better views to better outcome. *Singapore Med J* 2009; **50**: 763-767 [PMID: 19710972]

50 **Hellan M**, Anderson C, Ellenhorn JD, Paz B, Pigazzi A. Short-term outcomes after robotic-assisted total mesorectal excision for rectal cancer. *Ann Surg Oncol* 2007; **14**: 3168-3173 [PMID: 17763911 DOI: 10.1245/s10434-0079544-z]

51 **Mirnezami AH**, Mirnezami R, Venkatasubramaniam AK, Chandrakumaran K, Cecil TD, Moran BJ. Robotic colorectal surgery: hype or new hope? A systematic review of robotics in colorectal surgery. *Colorectal Dis* 2010; **12**: 1084-1093 [PMID: 19594601 DOI: 10.1111/j.1463-1318.2009.01999.x]

52 **Scarpinata R**, Aly EH. Does robotic rectal cancer surgery offer improved early postoperative outcomes? *Dis Colon Rectum* 2013; **56**: 253-262 [PMID: 23303155 DOI: 10.1097/DCR.0b013e3182694595]

53 **Mak TW**, Lee JF, Futaba K, Hon SS, Ngo DK, Ng SS. Robotic surgery for rectal cancer: A systematic review of current practice. *World J Gastrointest Oncol* 2014; **6**: 184-193 [PMID: 24936229 DOI: 10.4251/wjgo.v6.i6.184]

54 **Lanfranco AR**, Castellanos AE, Desai JP, Meyers WC. Robotic surgery: a current perspective. *Ann Surg* 2004; **239**: 14-21 [PMID: 14685095]

55 **Luca F**, Valvo M, Ghezzi TL, Zuccaro M, Cenciarelli S, Trovato C, Sonzogni A, Biffi R. Impact of robotic surgery on sexual and urinary functions after fully robotic nerve-sparing total mesorectal excision for rectal cancer. *Ann Surg* 2013; **257**: 672-678 [PMID: 23001075 DOI: 10.1097/SLA.0b013e318269d03b]

56 **Diana M**, Marescaux J. Robotic surgery. *Br J Surg* 2015; **102**: e15-e28 [PMID: 25627128 DOI: 10.1002/bjs.9711]

57 **Hance J**, Rockall T, Darzi A. Robotics in colorectal surgery. *Dig Surg* 2004; **21**: 339-343 [PMID: 15731560 DOI: 10.1159/000081350]

58 **Kurmann A**, Vorburger SA, Candinas D, Beldi G. Operation time and body mass index are significant risk factors for surgical site infection in laparoscopic sigmoid resection: a multicenter study. *Surg Endosc* 2011; **25**: 3531-3534 [PMID: 21638185 DOI: 10.1007/s00464-011-1753-7]

59 **Broholm M**, Pommergaard HC, Gögenür I. Possible benefits of robot-assisted rectal cancer surgery regarding urological and sexual dysfunction: a systematic review and meta-analysis. *Colorectal Dis* 2015; **17**: 375-381 [PMID: 25515638 DOI: 10.1111/codi.12872]

60 **Rullier E**, Laurent C, Garrelon JL, Michel P, Saric J, Parneix M. Risk factors for anastomotic leakage after resection of rectal cancer. *Br J Surg* 1998; **85**: 355-358 [PMID: 9529492 DOI: 10.1046/j.1365-2168.1998.00615.x]

61 **Vermeer TA**, Orsini RG, Daams F, Nieuwenhuijzen GA, Rutten HJ. Anastomotic leakage and presacral abscess formation after locally advanced rectal cancer surgery: Incidence, risk factors and treatment. *Eur J Surg Oncol* 2014; **40**: 1502-1509 [PMID: 24745995 DOI: 10.1016/j.ejso.2014.03.019]

62 **Liu Y**, Wan X, Wang G, Ren Y, Cheng Y, Zhao Y, Han G. A scoring system to predict the risk of anastomotic leakage after anterior resection for rectal cancer. *J Surg Oncol* 2014; **109**: 122-125 [PMID: 24318774 DOI: 10.1002/jso.23467]

63 **Buchs NC**, Gervaz P, Secic M, Bucher P, Mugnier-Konrad B, Morel P. Incidence, consequences, and risk factors for anastomotic dehiscence after colorectal surgery: a prospective monocentric study. *Int J Colorectal Dis* 2008; **23**: 265-270 [PMID: 18034250 DOI: 10.1007/s00384-007-0399-3]

64 **Nagtegaal ID**, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. *J Clin Oncol* 2002; **20**: 1729-1734 [PMID: 11919228 DOI: 10.1200/JCO.2002.07.010]

**P-Reviewer:** Agresta F, Aly EH, Brisinda G, Ouaissi M, Stanojevic GZ

**S-Editor:** Qiu S **L-Editor: E-Editor:**

**Figure 1 Flow diagram of literature search.**

**Table 1 Studies overview**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **Study design** | **Surgical technique** | **Platform** | **No. of pts Robot**  | **No. of pts Lap** | **No. of pts Open** |
| Park *et al*[8] | 2015 | South Korea | Comparative | Hybrid | DV | 133 | 84 |  |
| Levic *et al*[9] | 2014 | Denmark | Comparative | NS | DV | 56 | 36 |  |
| Yoo *et al*[10] | 2014 | South Korea | Comparative | Tot rob | NS | 44 | 26 |  |
| Koh *et al*[11] | 2014 | Singapore | Comparative | NS | NS | 19 | 19 |  |
| Melich *et al*[12] | 2014 | Canada | Comparative | Tot rob | DV | 92 | 106 |  |
| Barnajian *et al*[13] | 2014 | United States | Comparative | Hybrid | DV-S | 20 | 20 | 20 |
| Ielpo *et al*[14] | 2014 | Spain | Comparative | Tot rob | NS | 56 | 87 |  |
| Tam *et al*[15] | 2014 | United States | Comparative | Hybrid | DV | 21 | 21 |  |
| Ghezzi *et al*[16] | 2014 | Brazil | Comparative | Tot rob | DV-S | 65 |  | 109 |
| Kuo *et al*[17] | 2014 | Taiwan | Comparative | Tot rob | DV | 36 | 28 |  |
| Park *et al*[18] | 2014 | South Korea | Comparative | Hybrid | DV | 32 | 32 |  |
| Saklani *et al*[19] | 2013 | South Korea | Comparative | NS | NS | 74 | 64 |  |
| Fernandez *et al*[20] | 2013 | United States | Comparative  | Hybrid | DV-S | 13 | 59 |  |
| Erguner *et al*[21] | 2013 | Turkey | Comparative | Hybrid | NS | 27 | 37 |  |
| D’Annibale *et al*[22] | 2013 | Italy | Comparative | Tot rob | DV-S | 50 | 50 |  |
| Kang *et al*[23] | 2013 | South Korea | Comparative | Tot rob | NS | 165 | 165 | 165 |
| Park *et al*[24] | 2013 | South Korea | Comparative | Hybrid | DV | 40 | 40 |  |
| Kim *et al*[25] | 2012 | South Korea | Comparative | Tot rob | DV | 62 | 147 |  |
| Kim *et al*[26] | 2012 | South Korea | Comparative | Hybrid | DV | 30 | 39 |  |
| Bertani *et al*[27] | 2011 | Italy | Comparative | Tot rob | DV | 52 |  | 34 |
| Kwak *et al*[28] | 2011 | South Korea | Comparative | Tot rob | DV | 59 | 59 |  |
| Baek *et al*[29] | 2011 | United States | Comparative | NS | NS | 41 | 41 |  |
| Park *et al*[30] | 2011 | South Korea | Comparative | Hybrid | DV | 52 | 123 | 88 |
| Patriti *et al*[31] | 2009 | Italy | Comparative | Hybrid | DV | 29 | 37 |  |
| Baik *et al*[32] | 2008 | South Korea | Comparative | Hybrid  | DV  | 18 | 18 |  |
| Pigazzi *et al*[33] | 2006 | United States | Comparative | Hybrid | DV | 6 | 6 |  |
| Parisi *et al*[34] | 2014 | Italy | Case series | Hybrid | DV Si | 40  |  |  |
| Baek *et al*[35] | 2014 | South Korea | Case series | NS | NS | 182 |  |  |
| Shiomi *et al*[36] | 2014 | Japan | Case series | Hybrid | DV | 113 |  |  |
| Kim *et al*[37] | 2014 | South Korea | Case series | Tot rob | DV-S | 200 |  |  |
| Stanciulea *et al*[38] | 2013 | Romania | Case series | Tot rob | DV-Si | 100 |  |  |
| Zawadzki *et al*[39] | 2013 | United States | Case series | Hybrid | DV | 77 |  |  |
| Sng *et al*[40] | 2013 | South Korea | Case series | Tot rob | DV-S | 197 |  |  |
| Du *et al*[41] | 2013 | China | Case series | Tot rob | DV | 22 |  |  |
| Alimoglu *et al*[42] | 2012 | Turkey | Case series | Tot rob | DV | 7 |  |  |
| Akmal *et al*[43] | 2012 | United States | Case series | Hybrid | DV | 80 |  |  |
| Park *et al*[44] | 2012 | United States | Case series | Hybrid | DV-S | 30? |  |  |
| Kang *et al*[45] | 2011 | South Korea | Case series | Hybrid | DV | 389 |  |  |
| deSouza *et al*[46] | 2010 | United States | Case series | Hybrid | DV | 44 |  |  |
| Pigazzi *et al*[47] | 2010 | United States | Case series | Hybrid | DV | 143 |  |  |
| Choi *et al*[48] | 2009 | South Korea | Case series | Tot rob | DV | 50 |  |  |
| Ng *et al*[49] | 2009 | Singapore | Case series | Hybrid | DV | 8 |  |  |
| Hellan *et al*[50] | 2007 | United States | Case series  | Hybrid | DV | 39 |  |  |

Tot rob: Totally Robotic; DV: Da Vinci; NS: Not specified.

 **Table 2 Demographics and preoperative data**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **ASA** |  | **Type of operation** |
| **Ref.** | **M/F** | **Age** | **BMI** | **1**  | **2** | **3** | **4** | **Preop CHT** | **AR** | **LAR** | **ULAR** | **APR** |
| Park *et al*[8] | 86/47 | 59.2 (32-86) | 23.1 (14.6-32.8) | 94 | 31 | 8 | 0 | 15 | 100 | 33 | 0 | 0 |
| Levic *et al*[9] | 34/22 | 65 (23-83) | 24.8 (16-34.5) | 17 | 35 | 4 | 0 | 15 | 0 | 411 | 0 | 15 |
| Yoo *et al*[10] | 35/9 | 59.77 (+ 12.33) | 24.13 (+ 3.33) | 26 | 17 | 1 | 0 | 24 | 0 | 0 | 44 | 0 |
| Koh *et al*[11] | 15/4 | 62 (47-92) | - | 5 | 14 | 0 | 0 | 8 | 0 | 0 | 17 | 2 |
| Melich *et al*[12] | 52/40 | 60 (57.7-62.2) | 23.1 (22.5-23.7) | 1 (1-3) | 13 | 0 | 92 | 0 | 0 |
| Barnajian *et al*[13] | 12/8 | 62 (44-82) | 22 (18-31) | 0 | 4 | 16 | 0 | 10 | 0 | 15 | 0 | 5 |
| Ielpo B14 | 25/31 | 43.4 (+ 11) | 22.8 (+2.5) | 11 | 32 | 11 | 0 | 46 | 0 | 40 | 1 | 15 |
| Tam *et al*[15] | 10/11 | 60 (41-73) | 25 (20-37) | \_ | \_ | \_ | \_ | 18 | 11 | 1 | 4 | 5 |
| Ghezzi *et al*[16] | 41/24 | 61  | 24.7 | 12 | 49 | 4 | 0 | 47 | 0 | 44 | 11 | 102 |
| Kuo *et al*[17] | 21/15 | 55.9 (30-89) | - | 0 | 33 | 3 | 0 | 28 | 0 | 0 | 36 | 0 |
| Park *et al*[18] | 32/0 | - | 23.8 | - | - | - | - | 15 (+RT) | 0 | 22 | 9 | 1 |
| Saklani *et al*[19] | 50/24 | 59.6 (32-85) | 23.4 (16.9-29.8) | 50 | 24 | 0 | 0 | 74 | 0 | 46 | 26 | 2 |
| Fernandez *et al*[20] | 13/0 | 67.9 (+ 2.1) | - | 0 | 0 | 11 | 2 | 10 | 0 | 5 | 0 | 8 |
| Erguner *et al*[21] | 14/13 | 54 (24-78) | 28.3 (19.8-30.8) | - | - | - | - | 4 | 0 | 27 | 0 | 0 |
| D’Annibale *et al*[22] | 30/20 | 66 (+ 12.1) | - | - | - | - | - | 34 (+RT) | 17 | 33 | 0 | 0 |
| Kang *et al*[23] | 104/61 | 61.2 (+ 11.4) | 23.1 (+ 2.8) | 109 | 56 | 0 | 0 | 39 | 1653 | 0 | 0 | 0 |
| Park *et al*[24] | 41/21 | 56 | 24.2  | 33 | 28 | 1 | 0 | 9 | 0 | 51 | 10 | 1 |
| Kim *et al*[25] | 28/12 | 57.3 | 23.9 | 27 | 9 | 4 | 0 | 32 | 0 | 0 | 40 | 0 |
| Kim *et al*[26] | 18/12 | 54.13 (+ 8.52) | 24.36 (+ 2.4) | 29 | 1 | 0 | 0 | 10 | 29 | 13 | 0 | 0 |
| Bertani *et al*[27] | 31/21 | 59.6 (+ 11.6) | 24.8 (+ 3.62) | 49 | 3 | 24 | 0 | 52 | 0 | 0 |
| Kwak *et al*[28] | 39/20 | 60 (53-68) | 23.3 (21.8-25.2) | 28 | 27 | 4 | 0 | 8 (RT) | 0 | 54 | 5 | 0 |
| Baek *et al*[29] | 25/16 | 63.6 (48-87) | - | 0 | 18 | 22 | 1 | 33 | 0 | 33 | 2 | 6 |
| Park *et al*[30] | 28/24 | 57.3 | 23.7 | 21 | 26 | 5 | 0 | 12 (+RT) | 52 | 0 | 0 | 0 |
| Patriti *et al*[31] | 11/18 | 68 | 24 | 2 | 13 | 14 | 0 | 7 (+RT) | 29 | 0 | 0 | 0 |
| Baik *et al*[32] | 14/4 | 57.3 (37-79) | 22.8 (19.4-31.7) | 12 | 6 | 0 | 0 | - | 18 | 0 | 0 | 0 |
| Pigazzi *et al*[33] | 2/4 | 60 (42-78) | 31 (25-36) | 0 | 2 | 4 | 0 | 2 | 0 | 6 | 0 | 0 |
| Parisi *et al*[34] | 19/21 | 67 (39-86) | 25.22 (18.36-33.20) | 20 | 14 | 6 | 0 | 17 | 0 | 35 | 0 | 5 |
| Baek *et al*[35] | 117/65 | 57.6 (26-78) | 23.4 (14.8-30.5) | 111 | 65 | 6 | 0 | 50 | 0 | 182 | 0 | 0 |
| Shiomi *et al*[36] | 78/35 | 64 (23-84) | 23.4 (16.7-30.6) | 39 | 74 | 0 | 0 | 3 | 11 | 71 | 23 | 8 |
| Kim *et al*[37] | 134/66 | 58.15  | 23.85 | - | - | - | - | 43 | 0 | 200 | 0 | 0 |
| Stanciulea *et al*[38] | 66/34 | 62 (32-84) | 26 (16.4-38) | - | - | - | - | 58 | 30 | 39 | 8 | 23 |
| Zawadzki *et al*[39] | 45/32 | 60.1 (34-82) | 28 (18-43) | 62 | 15 | 0 | 48 | 0 | 68 | 9 | 0 | 0 |
| Sng *et al*[40] | 131/66 | 60 (20-89) | 23.5 (16.9-33.1) | 117 | 71 | 9 | 0 | 54 | 3 | 126 | 55 | 13 |
| Du *et al*[41] | 14/8 | 56.4 (+ 7.8) | 22.5 (+ 2.1) | - | - | - | - | - | 0 | 22 | 0 | 0 |
| Alimoglu *et al*[42] | 5/2 | 52.9 (32-88) | - | - | - | - | - | 4 | 0 | 0 | 0 | 7 |
| Akmal *et al*[43] | 50/30 | 60.35 (24-85) | 27.2 (18-44) | 0 | 37 | 39 | 4 | 62 | 0 | 40 | 21 | 19 |
| Park *et al*[44] | 16/14 | 58 | 27.6 | 0 | 12 | 18 | 0 | 20 | 0 | 5 | 19 | 6 |
| Kang *et al*[45] | 252/137 | 59 (26-86) | - | 280 | 107 | 2 | 0 | 72 | 382 | 13 | 0 | 6 |
| deSouza *et al*[46] | 28/16 | 63 | - | 4 | 27 | 13 | 0 | 31 | 0 | 30 | 6 | 8 |
| Pigazzi *et al*[47] | 87/56 | 62 (26-87) | 26.5 (16.5-44) | 0 | 0 | 57 | 93 (+RT) | 0 | 80 | 32 | 31 | 0 |
| Choi *et al*[48] | 32/18 | 58.5 (30-82) | 23.2 (19.4-29.2)  | 27 | 19 | 4 | 0 | 3 (+RT) | 0 | 40 | 8 | 2 |
| Ng KH49 | 5/3 | 55 (42-80) | - | - | - | - | - | - | 2 | 0 | 6 | 0 |
| Hellan *et al*[50] | 21/18 | 58 (26-84) | 26 (16-44) | 0 | 0 | 17 | 33 | 0 | 22 | 11 | 6 |

19 hartmann; 21 Posterior pelvic exenteration; 31 hartmann.

**Table 3 Operative data**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Patients**  | **Mesorectum** | **Technique** | **Mean operative time (min)** | **EBL (mL)** | **Conversion to open (%)** | **Stoma (%)** |
| Park *et al*[8] | 133 | RME | Hybrid | 205.7 (109-505) | 77.6 (0-700) | 0 (0) | 29 (21.8) |
| 84 | LME | Tot lap | 208.8 (94-407) | 82.3 (0-1100) | 6 (7.1) | 20 (23.8) |
| Levic *et al*[9] | 56 | RME | NS | 247 (135-111)1 | 50 (0-400)1 | 3 (5.4) | 31 (55.3) |
| 36 | LME | SP | 295 (108-465)1 | 35 (0-400)1 | 0 (0) | 9 (25) |
| Yoo *et al*[10] | 44 | RME | Tot rob | 316.43(+ 65.11) | 239.77 (+ 278.61) | 0 (0) | 44 (100) |
| 26 | LME | Tot lap | 286.77 (+ 51.46) | 215.38 (+ 247.29) | 0 (0) | 26 (100) |
| Koh *et al*[11] | 19 | RME | NS | 390 (289-771)1 | - | 1 (5.2) | 17 (89) |
| 19 | LME | HAL  | 225 (130-495)1 | - | 5 (26.3) | 0 (0) |
| Melich *et al*[12] | 92 | RME | Tot rob | 285 (266-305) | 201 (165-237) | 1 (1.1) | - |
| 106 | LME | Tot lap | 262 (252-272) | 232 (191-272) | 4 (3.8) | - |
| Barnajian *et al*[13] | 20 | RME | Hybrid | 240 (150-540)1 | 125 (50-650)1 | 0 (0) | 11 (55) |
| 20 | LME | Tot lap | 180 (140-480)1 | 175 (50-900)1 | 2 (10.5) | 11 (55) |
| 20 | OME | Open | 240 (115-475)1 | 250 (50-800)1 | na | 12 (60) |
| Ielpo *et al*[14] | 56 | RME | Tot rob | 309 (150-540) | 280 (0-4000) | 2 (3.5) | 28 (50) |
| 87 | LME | Tot lap | 252 (180-420) | 240 (0-4000) | 10 (11.5) | 53 (60.9) |
| Tam *et al*[15] | 21 | RME | Hybrid | 274.8 (189-449) | 252.6 (30-2000) | 1 (4.7) | 13 (62) |
| 21 | LME | Tot lap | 236.3 (171-360) | 271.4 (50-1200) | 0 (0) | 11 (52) |
| Ghezzi *et al*[16] | 65 | RME | Tot rob | 299 (+58) | 0 (0-175)1 | 1 (1.5) | 51 (91.1) |
| 109 | OME | Open | 207 (+56.5) | 150 (0-400)1 | na | 66 (63.3) |
| Kuo *et al*[17] | 36 | RME | NS | 485.8 (315-720) | 80 (30-200) | 0 (0) | 7 (19.4) |
| 28 | LME | Tot lap | 374.3 (210-570) | 103.6 (30-250) | 0 (0) | 13 (46.4) |
| Park *et al*[18] | 32 | RME | Hybrid | - | - | - | 3 (9.4) |
| 32 | LME | Tot lap | - | - | - | 3 (9.4) |
| Saklani *et al*[19] | 74 | RME | NS | 365.2 (150-710) | 180 (0-1100) | 1 (1.4) | 53 (71.6) |
| 64 | LME | Tot lap | 311.6 (180-530) | 210 (0-1200) | 4 (6.3) | 35 (54.7) |
| Fernandez *et al*[20] | 13 | RME | Hybrid | 528 (416-700)1 | 157 (50-550)1 | 1 (8) | - |
| 59 | LME | HAL | 344 (183-735)1 | 200 (25-1500)1 | 10 (17) | - |
| Erguner *et al*[21] | 27 | RME | Hybrid | 280 (175-480) | 50 (20-100) | 0 (0) | 19 (70.3) |
| 37 | LME | Tot lap | 190 (110-300) | 125 (50-400) | 0 (0) | 13 (35.1) |
| D’Annibale *et al*[22] | 50 | RME | Tot rob | 270 (240-315)1 | - | 0 (0) | - |
| 50 | LME | Tot lap | 280 (240-350)1 | - | 6 (12) | - |
| Kang *et al*[23] | 165 | RME | Tot rob | 309.7 (+ 115.2) | 133 (+ 192.3) | 1 (0.6) | 41 (25) |
| 165 | LME | Tot lap | 277.8 (+ 81.9) | 140.1 (+ 216.4) | 3 (1.8) | 43 (27.2) |
| 165 | OME | Open | 252.6 (+ 88.1) | 275.4 (+ 368.4) | na | 47 (31.8) |
| Kim *et al*[25] | 62 | RME | Tot rob | 390 (+ 97) | - | 3 (4.8) | 22 (35.5) |
| 147 | LME | Tot lap | 285 (+ 80) | - | 5 (3.4) | 34 (23.1) |
| Park *et al*[24] | 40 | RME | Hybrid | 235.5 (+ 57.5) | 45.7 (+40) | 0 (0) | 14 (35) |
| 40 | LME | Tot lap | 185.4 (+ 72.8) | 59.2 (+35.8) | 0 (0) | 6 (15) |
| Kim *et al*[26] | 30 | RME | Hybrid | - | - | - | - |
| 39 | LME | Tot lap | - | - | - | - |
| Bertani *et al*[27] | 52 | RME | Tot rob | 260 (190-570) | 100 (50-1000) | - | - |
| 34 | OME | Tot lap | 164 (100-350) | 120 (50-2000) | - | - |
| Kwak *et al*[28] | 59 | RME | Tot rob | 270 (241-325)1 | - | 0 (0) | 25 (42.4) |
| 59 | LME | Tot lap | 228 (177-254)1 | - | 2 (3.4) | 26 (44.1) |
| Baek *et al*[29] | 41 | RME | NS | 296 (150-520) | 200 (20-2000)1 | 3 (7.3) | 33 (94.3) |
| 41 | LME | NS | 315 (174-584) | 300 (17-1000)1 | 9 (22) | 14 (40) |
| Park *et al*[30] | 52 | RME | Hybrid | 232.6 (+ 54.2) | - | 0 (0) | 1 (1.9) |
| 123 | LME | Tot lap | 158.1 (+ 49.2) | - | 0 (0) | 5 (4.1) |
| 88 | OME | Open | 233.8 (+ 59.2) | - | na | 4 (4.5) |
| Patriti *et al*[31] | 29 | RME | Hybrid | 202 (+ 12) | 137.4 (+156) | 0 (0) | 0 (0) |
| 37 | LME | Tot lap | 208 (+ 7) | 127(+169) | 7 (19) | 0 (0) |
| Baik *et al*[32] | 18 | RME | Hybrid | 217.1 (149-315) | - | 0 (0) | - |
| 18 | LME | Tot lap | 204.3 (114-297) | - | 2 (11) | - |
| Pigazzi *et al*[33] | 6 | RME | Hybrid | 264 (192-318) | 104 (50-200) | 0 (0) | - |
| 6 | LME | Tot lap | 258 (198-312) | 150 (50-300) | 0 (0) | - |
| Parisi *et al*[34] | 40  | RME | Hybrid | 340 (235-460)1 | 50 (20-250)1 | 0 (0) | 22 (55) |
| Baek *et al*[35] | 182 | RME | NS | - | - | - | - |
| Shiomi *et al*[36] | 113 | RME | Hybrid | 302 (135-683)1 | 17 (0-690)1 | 0 (0) | - |
| Kim *et al*[37] | 200 | RME | Tot rob | 308.3  | - | 1 (0.5) | 9 (4.5) |
| Stanciulea *et al*[38] | 100 | RME | Tot rob | - | 150 (0-250)1 | 4 (4) | 64 (64) |
| Zawadzki *et al*[39] | 77 | RME | Hybrid  | 327 (178-510)1 | 189 (30-1000)1 | 3 (3.9) | 53 (69) |
| Sng *et al*[40] | 197 | RME | Tot rob | 278.7 (145-515) | < 50 (50-1500)1 | 0 (0) | - |
| Du *et al*[41] | 22 | RME | Tot rob | 220 (152-286) | 33 (10-70) | 0 (0) | - |
| Alimoglu *et al*[42] | 7 | RME | Tot rob | - | - | 0 (0) | - |
| Akmal *et al*[43] | 80 | RME | Hybrid | 303.5  | - | 4 (5) | 46 (57.5) |
| Park *et al*[44] | 30 | RME | Hybrid | 369 (306-410)1 | 100 (75-200)1 | - | - |
| Kang *et al*[45] | 389 | RME | Hybrid | 322.35  | - | 3 (0.7) | 93 (24) |
| deSouza *et al*[46] | 44 | RME | Hybrid | 347 (155-510)1 | 150 (50-1000)1 | - | 34 (77.2) |
| Pigazzi *et al*[47] | 143 | RME | Hybrid | 297 (90-660) | 283 (0-6000) | 7 (4.9) | 71 (50) |
| Choi *et al*[48] | 50 | RME | T Tot rob | 304.8 (190-485) | - | 0 (0) | 16 (32) |
| Ng *et al*[49] | 8 | RME | Hybrid | 278.7 (145-515) | - | 0 (0) | 6 (75) |
| Hellan *et al*[50] | 39 | RME | Hybrid | 285 (180-540)1 | 200 (25-6000)1 | 1 (2.5) | 4 (10.2) |

Tot rob: Totally robotic; Tot lap: Totally laparoscopic; HAL: Hand assisted laparoscopy; SP: Single port; NS: Not specified. 1Median.

**Table 4 Postop data**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Pts**  | **Mesorectum** | **Flatus (POD)** | **Liquid diet (POD)** | **Solid diet (POD)** | **Length of stay (d)** | **30 d mortality (%)** | **Reinterventions (%)** |  |
| Park *et al*[8] | 133 | RME | 2.42 (1-6) | - | 4.92 (3-11) | 5.86 (4-14) | 0 (0) | - |  |
| 84 | LME | 2.47 (1-6) | - | 5.19 (2-11) | 6.54 (3-25) | 0 (0) | - |  |
| Levic *et al*[9] | 56 | RME | - | - | - | 8 (4-100) | 0 (0) | - |  |
| 36 | LME | - | - | - | 7 (3-51) | 2 (5.6) | - |  |
| Yoo *et al*[10] | 44 | RME | - | - | 2.58 (+ 1.62) | 11.41 (+ 5.56) | 0 (0) | - |  |
| 26 | LME | - | - | 2.48 (+ 1.53) | 11.04 (+ 6.33) | 0 (0) | - |  |
| Koh *et al*[11] | 19 | RME | - | - | - | 7 (4-21)1 | 0 (0) | 1 (5.2) | Bleeding |
| 19 | LME | - | - | - | 6 (4-28)1 | 0 (0) | 3 (15.7) | Adhesive SBO, colonic infarction, anastomotic leak |
| Melich *et al*[12] | 92 | RME | - | - | - | 9.6 (8.3-11) | - | 6 (6.5) | 6 leak/abscess |
| 106 | LME | - | - | - | 9.9 (8.5-11.3) | - | 5 (4.7) | 4 leak/ abscess, 1 obstruction due to adhesions |
| Barnajian *et al*[13] | 20 | RME | 3 (1-8)1 | - | 4 (2-9)1 | 6 (4-31)1 | 0 (0) | 2 (10) | Presacral bleeding, pelvic abscess |
| 20 | LME | 4 (3-13)1 | - | 4 (4-14)1 | 7 (5-36)1 | 0 (0) | 1 (5) | Pancreatic tail injury |
| 20 | OME | 4 (2-8)1 | - | 4.5 (2-9)1 | 7 (3-16)1 | 0 (0) | 2 (10) | Presacral bleeding, enterotomy |
| Ielpo *et al*[14] | 56 | RME | - | - | - | 13 (5-60) | 0 (0) | 3 (5.3) | ns |
| 87 | LME | - | - | - | 10 (5-16) | 0 (0) | 3 (3.4) | ns |
| Tam *et al*[15] | 21 | RME | - | - | - | 8.7 (4-23) | - | 0 (0) |  |
| 21 | LME | - | - | - | 6 (3-14) | - | 1 (5) | bleeding |
| Ghezzi *et al*[16] | 65 | RME | 2 (1-2) | 1 (1-2) | - | 6 (5-8)1 | 0 (0) | 3 (4.6) | ns |
| 109 | OME | 3 (2-5) | 5 (4-6) | - | 9 (8-10)1 | 0 (0) | 2 (1.8) | ns |
| Kuo *et al*[17] | 36 | RME | 2.9 (1-6) | - | 6.4 (4-12) | 14.2 (9-27) | - | - |  |
| 28 | LME | 3.4 (1-11) | - | 5.8 (3-16) | 15.1 (7-57) | - | - |  |
| Park *et al*[18] | 32 | RME | - | - | - | - | - | - |  |
| 32 | LME | - | - | - | - | - | - |  |
| Saklani *et al*[19] | 74 | RME | 2.45 (1-10) | - | 4.6 (2-13) | 8 (4-21) | 0 (0) | - |  |
| 64 | LME | 2.48 (1-6) | - | 5.1 (2-14) | 9.2 (5-29) | 0 (0) | - |  |
| Fernandez *et al*[20] | 13 | RME | - | - | - | 131 | 0 (0) | 2 (15) | SBO |
| 59 | LME | - | - | - | 8 1 | 1 (2) | 7 (12) | Ns |
| Erguner *et al*[21] | 27 | RME | - | - | - | - | 1 (3.7) | 1 (3.7) | Colonic necrosis |
| 37 | LME | - | - | - | - | 1 (2.7) | 3 (8.1) | 1 ileostomy retraction, 2 anastomotic leak |
| D’Annibale *et al*[22] | 50 | RME | - | 3 (3-5)1 | - | 8 (7-11)1 | 0 (0) | 0 (0) |  |
| 50 | LME | - | 5 (4-6)1 | - | 10 (8-14)1 | 0 (0) | 3 (6) | anastomotic leak |
| Kang *et al*[23] | 165 | RME | 2.2 (+1.1) | - | 4.5 (+1.9) | 10.8 (+5.5) | 0 (0) | 15 (9) | ns |
| 165 | LME | 2.4 (+1.2) | - | 5.2 (+2.4) | 13.5 (+9.2) | 0 (0) | 25 (15) | ns |
| 165 | OME | 3 (+1.4)  | - | 6.4 (+2.5) | 16 (+ 8.6) | 0 (0) | 9 (5.4) | ns |
| Kim *et al*[25] | 62 | RME | - | - | 6 (+5) | 12 (+6) | - | - |  |
| 147 | LME | - | - | 7 (+5) | 14 (+9) | - | - |  |
| Park *et al*[24] | 40 | RME | 2.4 (+1.6) | - | 7.5 (+3.5) | 10.6 (+4.2) | 0 (0) | 2 (5) | Anastomotic leak  |
| 40 | LME | 2.5 (+1.3) | - | 7.7 (+2.3) | 11.3 (+3.6) | 0 (0) | 1 (2.5) | Anastomostic leak |
| Kim *et al*[26] | 30 | RME | - | - | - | - | - | - |  |
| 39 | LME | - | - | - | - | - | - |  |
| Bertani *et al*[27] | 52 | RME | 2 (1-5) | 2 (1-13) | - | 6 (4-51)1 | - | 2 (4) |  |
| 34 | OME | 3 (1-9) | 3 (2-12) | - | 7 (4-24)1 | - | 0 (0) |  |
| Kwak *et al*[28] | 59 | RME | - | - | - | - | - | - |  |
| 59 | LME | - | - | - | - | - | - |  |
| Baek *et al*[29] | 41 | RME | - | 2.3 (1-13) | - | 6.5 (2-33) | 0 (0) | - |  |
| 41 | LME | - | 2.4 (1-9) | - | 6.6 (3-20) | 0 (0) | - |  |
| Park *et al*[30] | 52 | RME | 3.2 (+1.8) | - | 6.7 (+3.8) | 10.4 (+4.7) | 0 (0) | - |  |
| 123 | LME | 3 (+1.1) | - | 6.1 (+2.7) | 9.8 (+3.8) | 0 (0) | - |  |
| 88 | OME | 4.4 (+3) | - | 7.6 (+3.3) | 12.8 (+7.1) | 1 (1.1) | - |  |
| Patriti *et al*[31] | 29 | RME | - | - | - | 11.9 (6-29) | 0 (0) | - | - |
| 37 | LME | - | - | - | 9.6 (5-37) | 0 (0) | - | - |
| Baik *et al*[32] | 18 | RME | 1.8 (1-2)1 | - | - | 6.9 (5-10)1 | - | 0 (0) |  |
| 18 | LME | 2.4 (1-6)1 | - | - | 8.7 (6-12)1 | - | 0 (0) |  |
| Pigazzi *et al*[33] | 6 | RME | - | - | - | 4.5 (3-11) | - | 0 (0) |  |
| 6 | LME | - | - | - | 3.6 (3-6) | - | 0 (0) |  |
| Parisi *et al*[34] | 40  | RME | 1 (1-3)1 | 1 (1-5)1 | 2 (2-6)1 | 5 (3-18)1 | 0 (0) | 1 (2.5) | Anastomotic leak |
| Baek *et al*[35] | 182 | RME | - | - | - | - | - | - | - |
| Shiomi *et al*[36] | 113 | RME | 2 (1-3)1 | 3 (3-7)1 | - | 7 (6-24)1 | 0 (0) | 2 (1.8) | Anastomotic leak |
| Kim *et al*[37] | 200 | RME | 2.4 | - | 5 | 10.7 |  | 16 (8) | ns |
| Stanciulea *et al*[38] | 100 | RME | - | - | - | 10 (6-38)1 | - | 6 (6) | 3 anastomotic leak, 1 bowel obstruction, 1 bleeding, 1 bowel injury |
| Zawadzki *et al*[39] | 77 | RME | - | - | - | 6.4 (3-26) | 0 (0) | 3 (3.9) | anastomotic leak |
| Sng *et al*[40] | 197 | RME | - | - | - | 9 (5-122)1 | - | - |  |
| Du *et al*[41] | 22 | RME | 2.6 (1.41-4.37)1 | - | - | 7.8 (7-13)1 | - | - |  |
| Alimoglu *et al*[42] | 7 | RME | - | - | - | 8.1 (5-10)1 | 0 (0) | 0 (0) |  |
| Akmal *et al*[43] | 80 | RME | - | 2.75 (1-19) | - | 7.55 (2-33) | 0 (0) | - |  |
| Park *et al*[44] | 30 | RME | - | - | - | 4 (3-6)1 | 0 (0) | - |  |
| Kang *et al*[45] | 389 | RME | 2.3 | 3.9 | - | 13.5  | 0 (0) | 36 (9.2) | ns |
| deSouza *et al*[46] | 44 | RME | - | - | - | 5 (3-36)1 | 1 (0.46) | 2 (0.92) | 1 anastomotic leak |
| Pigazzi *et al*[47] | 143 | RME | - | 2.7 (1-19) | - | 8.3 (2-33) | 0 (0) | - |  |
| Choi *et al*[48] | 50 | RME | 1.9 (1-3) | 2.6 (2-12) | - | 9.2 (5-24) | - | 0 (0) |  |
| Ng *et al*[49] | 8 | RME | - | - | - | 5 (4-30)1 | 0 (0) | - | - |
| Hellan *et al*[50] | 39 | RME | - | 2 (1-11)1 | - | 4 (2-22)1 | 0 (0) | 4 (10.3) | Anastomotic leak |

1Values are expressed as mean, solid diet includes soft diet. SBO: Small bowel obstruction.

**Table 5 Complications according to Clavien Dindo classification**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Pts**  | **Mesorectum** | **Complicated pts (%)** | **1 (%)** | **2 (%)** | **3 (%)** | **4 (%)** | **5 (%)** |
| **3a** | **3b** |  |  |
| Park *et al*[8] | 133 | RME | 26 (19.5) | 11 (42.3) | 5 (19.2) | 9 (34.6) | 1 (3.8) |  |
|  | 84 | LME | 19 (22.6) | 7 (36.8) | 4 (21) | 6 (31.6) | 2 (10.5) |  |
| Yoo *et al*[10] | 44 | RME | 17 (38.6) | 13 (76.5) | 4 (23.5) |  |
| 26 | LME | 7 (26.9) | 5 (71.4) | 2 (28.5) |  |
| Koh *et al*[11] | 19 | RME | 3 (15.7) | 2 (66.7) |  | 1 (33.3) |  |  |
| 19 | LME | 7 (36.8) | 4 (57) |  | 3 (43) |  |  |
| Melich *et al*[12] | 92 | RME | 17 (18.4) | 11 (64.7) |  | 6 (35.3) |  |  |
| 106 | LME | 18 (17) | 13 (72.2) |  | 5 (27.8) |  |  |
| Barnajian *et al*[13] | 20 | RME | 8 (40) |  | 3 | 3 (37.5) | 2 (25) |  |  |
| 20 | LME | 4 (10) | 2 |  | 1 | 1 |  |  |
| 20 | OME | 8 (40) |  | 5 |  | 2 | 1 (33.3) |  |
| Ielpo *et al*[14] | 56 | RME | 15 (26.8) | 11 (73.3) | 4 (26.7) |
| 87 | LME | 20 (23) | 15 (75) | 5 (25) |
| Ghezzi *et al*[16] | 65 | RME | 27 (41.5) | 22 (81.5) | 5 (18.5) |  |
| 109 | OME | 45 (41.3) | 38 (84.5) | 7 (15.5) |  |
| Kuo *et al*[17] | 36 | RME | 11 (30.5) | 4 (36.3) | 3 (27.2) | 4 (36.3) |  |  |
| 28 | LME | 14 (50) | 11 (78.6) | 1 (7) | 2 (14.2) |  |  |
| Fernandez *et al*[20] | 13 | RME |  |  |  | 2 |  |  |
| 59 | LME |  |  |  |  |  |  |
| Erguner *et al*[21] | 27 | RME | 3 (11.1) | 2 (66.7) |  | 1 (33.3) |  |  |
| 37 | LME | 8 (21.6) | 5 (62.5) |  | 3 (37.5) |  |  |
| D’Annibale *et al*[22] | 50 | RME | 5 (10) | 5 (100) |  |  |  |  |
| 50 | LME | 10 (20) | 7 (70) |  | 3 (30) |  |  |
| Kang *et al*[23] | 165 | RME | 34 (20.6) | 16 (47.1) | 3 (8.8) |  |
| 165 | LME | 46 (27.9) | 20 (43.5) | 1 (2.2) |  |
| 165 | OME | 41 (24.8) | 30 (73.2) | 2 (4.9) |  |
| Park *et al*[24] | 40 | RME | 6 (15) | 4 (66.7) | 2 (33.3) |
| 40 | LME | 5 (12.5) | 4 (80) | 1 (20) |
| Park *et al*[30] | 52 | RME | 10 (19.2) | 6 (60) | 4 (40) |
| 123 | LME | 15 (12.2) | 9 (60) | 6 (40) |
| 88 | OME | 18 (20.5) | 9 (50) | 9 (50) |
| Baik *et al*[32] | 18 | RME | 4 (22.2) | 3 (75) | 1 (25) |  |  |  |  |
| 18 | LME | 1 (5.5) |  | 1 (100) |  |  |  |  |
| Pigazzi *et al*[33] | 6 | RME | 1 (16.6) |  | 1 (100) |  |  |  |  |
| 6 | LME | 1 (16.6) |  |  | 1 (100) |  |  |  |
| Parisi *et al*[34] | 40  | RME | 4 (10) | 1 (25) | 1 (25) |  | 2 (50) |  |  |
| Shiomi *et al*[36] | 113 | RME | 23 (20.3) | 10 (43.5) | 10 (43.5) | 1 (4.3) | 2 (8.7) |  |  |
| Kim *et al*[37] | 200 | RME |  |  |  | 16 (59.2) |  |  |  |
| Stanciulea *et al*[38] | 100 | RME | 18 (18) |  | 10 (55.5) | 2 (5.5) | 6(38.9) |  |  |
| Zawadzki *et al*[39] | 77 | RME |  |  | 2  | 3 |  |  |  |
| Sng *et al*[40] | 197 | RME | 74 (37) | 58 (78.3) | 5 (6.8) | 9 (12.1) | 1 (1.3) | 1 (1.3) |  |
| Du *et al*[41] | 22 (4.5) | RME | 1 (4.5) | 1 (100) | 0 |  |  |  |  |
| Alimoglu *et al*[42] | 7 | RME | 2 (28.5) | 2 (100) |  |  |  |  |  |
| Kang *et al*[45] | 389 | RME | 74 (19) | 34 (45.9) | 4 (5.4) | 36 (48.6) |  |  |  |
| deSouza *et al*[46] | 44 | RME | 19 (43) | 15 (79) | 1 (5.2) | 1 (5.2) | 1 (5.2) | 1 (5.2) |  |
| Choi *et al*[48] | 50 | RME | 9 (18) |  | 4 (44.4) | 5 (55.5) |  |  |  |
| Hellan *et al*[50] | 39 | RME | 15 (38.4) | 11 (73.3) | 4 (26.7) |  |  |  |  |

**Table 6 Short term oncologic outcomes**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Pts**  | **Mesorectum** | **DSF% (yrs)** | **LR (%)** | **Distant metastases (%)** | **OS % (yr)** | **F-u mo (median)** |
| Park *et al*[8] | 133 | RME | 81.9 (5) | 3 (2.3) | 16 (12) | 92.8 (5) | 58 (4-80) |
| 84 | LME | 78.7 (5) | 1 (1.2) | 14 (16.6) | 93.5 (5) | 58 (4-80) |
| Levic *et al*[9] | 56 | RME |  | 0 (0) | 8 (14.3) |  | 12 (1-31) |
| 36 | LME |  | 0 (0) | 2 (5.6) |  | 10 (1-33) |
| Yoo *et al*[10] | 431 | RME | 76.7 (3) | 6 (12.8) |  | 95.2 (3) | 33.9 (4.4-61.3) |
| 26 | LME | 75 (3) | 2 (8.3) |  | 88.5 (3) | 36.5 (3.7-69.9) |
| Ghezzi *et al*[16] | 65 | RME | 73.2 (5) | 2 (3.2) |  19 (29.6) | 85 (5) | 60 |
| 109 | OME | 69.5 (5) | 17.5 (16.1) |  26 (24.2) | 76.1 (5) | 60 |
| Saklani *et al*[19] | 74 | RME | 77.7 (3) | 2 (2.7) |  | 90 (3) | 30.1 (11-61)2 |
| 64 | LME | 78.8 (3) | 4 (6.3) |  | 92.1 (3) | 30.1 (11-61)2 |
| Kim *et al*[25] | 62 | RME |  | 0 (0) | 3 (4.2) | 98 (1,5) | 17.4 |
| 147 | LME |  | 1 (0.7) | 8 (5.4) | 98 (1.7) | 20.6 |
| Kwak *et al*[28] | 59 | RME |  | 1 (1.8) | 2 (3.6) |  | 17 (11-25) |
| 59 | LME |  | 1 (1.9) | 2 (3.7) |  | 13 (9-22) |
| Patriti *et al*[31] | 29 | RME | 100 (3) | 0 (0) | 0 (0) | 96.6 (2.4) | 29.22 |
| 37 | LME | 83.7 (3) | 2 (5.4) | 4 (6) | 97.2 (1.5) | 18.72 |
| Stanciulea *et al*[38] | 100 | RME |  | 2 (2) |  | 90 (3) | 24 (9-63) |
| Alimoglu *et al*[42] | 7 | RME | 100 (1) | 0 (0) | 0 (0) | 100 (1) | 12 (6-21)2 |
| Pigazzi *et al*[47] | 143 | RME | 77.6 (3) | 2 (1.4) | 13 (9) | 97 (3) | 17.4 (0.1-52.5)2 |

11 patient excluded (palliative ISR); 2Mean. DSF: Disease free survival rate; LR: Local recurrence; OS: Overall survival.

**Table 7 Histopathological data**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Pts**  | **Mesorectum** | **Harvested nodes**  | **Quality of mesorectum (complete)** | **Proximal margin (mm)** | **Distal margin (mm)** | **Distal margin** **+ (%)** | **CRM (mm)** | **CRM + (%)** | **pTpN stage (%)****0 1 2 3 4** |
| Park *et al*[8] | 133 | RME | 16.34 (2-43) | - | 111.7 (40-350) | 27.5 (10-140) | 0 (0) | - | 9~ (6.8) | 0 (0) | 49 (36.8) | 36 (27.1) | 48 (36.1) | 0 (0) |
| 84 | LME | 16.63 (2-49) | - | 105.1 (40-340) | 28.7 (10-90) | 0 (0) | - | 6~ (7.1) | 0 (0) | 22 (26.2) | 28 (33.3) | 34 (40.5) | 0 (0) |
| Levic *et al*[9] | 56 | RME | 21 (7-83)1 | 34 | - | 30 (5-80) | 1 (0.56) | 9 (0-60)1 | - | 3 (5.4) | 12 (21.4) | 20 (35.7) | 21 (37.5) | 0 (0) |
| 36 | LME | 13 (3-33)1 | 26 | - | 30 (5-75) | 0 (0) | 10 (1-43)1 | - | 1 (2.8) | 6 (16.7) | 15 (41.7) | 14 (38.8) | 0 (0) |
| Yoo *et al*[10] | 44 | RME | 13.93 (+ 9.27) | - | 225.2 (+ 102.5) | 13.3 (+ 9.7) | - | - | 4 (9.1) | 5 (11.4) | 14 (31.8) | 11 (25) | 9 (20.5) | 5 (11.4) |
| 26 | LME | 21.42 (+ 15.71) | - | 208.4 (+ 89.5) | 16.7 (+ 30) | - | - | 5 (19.2) | 1 (3.8) | 7 (26.9) | 8 (30.8) | 8 (30.8) | 2 (7.7) |
| Koh *et al*[11] | 19 | RME | 16 (4-24)1 | 19 | - | - | 1 (5.2) | - | 1~ (5.2) | 2(10.5) | 3 (15.7) | 4 (21) | 9 (47.3) | 1 (5.2) |
| 19 | LME | 14 (5-27)1 | 19 | - | - | 0 (0) | - | 0~ (0) | 0 (0) | 5 (26.3) | 4 (21) | 9 (47.3) | 1 (5.2) |
| Melich *et al*[12] | 92 | RME | 17.2 (15-19.5) | - | - | - | 1 (1.1) | - | 3 (3.3) | - | - | - | - | - |
| 106 | LME | 16.3 (14.4-18.1) | - | - | - | 0 (0) | - | 3 (2.8) | - | - | - | - | - |
| Barnajian *et al*[13] | 20 | RME | 14 (3-22)1 | 16 | - | 20.5 (5-50)1 | - | 10.5 (1-30)1 | - | 0 (0) | 6 (40) | 4 (25) | 10 (35) | 0 (0) |
| 20 | LME | 11 (4-18)1 | 19 | - | 21.5 (1-55)1 | - | 4 (0-30)1 | - | 0 (0) | 7 (35) | 3 (15) | 10 (50) | 0 (0) |
| 20 | OME | 12 (4-20)1 | 19 | - | 20.5 (1-45)1 | - | 8 (0-30)1 | - | 0 (0) | 8 (40) | 3 (15) | 9 (45) | 0 (0) |
| Ielpo *et al*[14] | 56 | RME | 10 (0-29) | - | - | - | - | - | 2~ (3.6) | 0 (0) | 14 (25) | 21 (37.5) | 21 (37.5) | 0 (0) |
| 87 | LME | 9 (0-17) | - | - | - | - | - | 2~ (2.3) | 0 (0) | 19 921.8) | 38 (43.6) | 30 (34.5) | 0 (0) |
| Tam *et al*[15] | 21 | RME | 19.7 (8-40) | - | - | 460 (10-180) | 0 (0) | - | 0 (0) | 2 (10) | 5 (24) | 4 (19) | 9 (43) | 1 (5) |
| 21 | LME | 14.8 (8-21) | - | - | 510 (5-80) | 1 (5) | - | 1 (5%) | 3 (14) | 7 (33) | 4 (19) | 7 (33) | 0 (0) |
| Ghezzi *et al*[16] | 65 | RME | 20.1  | - | - | 27 (16-44) | - | - | 0 (0) | 10 (15.4) | 5 (7.7) | 17 (26.2) | 27 (41.5) | 6 (9.2) |
| 109 | OME | 14.1 | - | - | 22 (15-30) | - | - | 2 (1.8) | 15 (13.8) | 10 (9.2) | 38 (34.9) | 42 (38.5) | 4 (3.7) |
| Kuo *et al*[17] | 36 | RME | 14 (2-33) | - | - | 22 (4-42) | 0 (0) | 6.7 (0-18) | 4 (11.1) | 7 (19.4) | 4 (11.1) | 11 (30.5) | 14 (38.8) | 0 (0) |
| 28 | LME | 13.9 (3-31) | - | - | 17.9 (1-60) | 1 (3.6) | 7 (0-16) | 4 (14.2) | 6 (21.4) | 2 (7.1) | 8 (28.6) | 12 (42.8) | 0 (0) |
| Park *et al*[18] | 32 | RME | - | - | - | - | - | - | - | - | - | - | - | - |
| 32 | LME | - | - | - | - | - | - | - | - | - | - | - | - |
| Saklani *et al*[19] | 74 | RME | 11.6 (1-36) | - | 128 (50-240) | 17 (1-60) | - | - | 3~(4) | 18 (24.3) | 16 (21.6) | 22 (29.7) | 18 (24.3) | 0 (0) |
| 64 | LME | 14.7 (1-27) | - | 140 (55-280) | 22 (2-70) | - | - | 1~ (1.6) | 8 (12.5) | 13 (20.3) | 23 (35.9) | 20 (31.3) | 0 (0) |
| Fernandez *et al*[20] | 13 | RME | 16 | 9 | - | - | 0 (0) | - | 0 (0) |  | - | - | - | - |
| 59 | LME | 20 | 24 | - | - | 1 (2) | - | 1 (2) |  | - | - | - | - |
| Erguner *et al*[21] | 27 | RME | 16 (3-38) | 19 | 120 (40-180) | 40 (30-80) | 0 (0) | 4 (2-8) | - | 0 (0) | 15 (55.5) | 11 (40.7) | 1 (3.7) | 0 (0) |
| 37 | LME | 16 (3-31) | 17 | 140 (45-230) | 25 (5-50) | 0 (0) | 4 (1-10) | - | 0 (0) | 17 (46) | 16 (43.2) | 4 (10.8) | 0 (0) |
| D’Annibale *et al*[22] | 50 | RME | 16.5 (11-44) | - | - | 30 (20-70) | - | - | 0 (0) | - | - | - | - | - |
| 50 | LME | 13.8 (4-29) | - | - | 30 (10-60) | - | - | 6 (12) | - | - | - | - | - |
| Kang *et al*[23] | 165 | RME | 15 (+ 9.4) | - | 120 (+ 49) | 19 (+ 14) | 0 (0) | - | 7 (4.2) | 4 (2.4) | 56 (33.9) | 51 (30.9) | 54 (32.7) | 0 (0) |
| 165 | LME | 15.6 (+ 9.1) | - | 113 (+ 51) | 20 (+ 17) | 0 (0) | - | 11 (6.7) | 9 (5.4) | 55 (33.1) | 47 (28.5) | 54 (32.7) | 0 (0) |
| 165 | OME | 17.4 (+ 10.9) | - | 114 (+ 55) | 22 (+ 17) | 0 (0) | - | 17 (10.3) | 14 (8.5) | 55 (33.3) | 41 (24.8) | 55 (33.3) | 0 (0) |
| Kim *et al*[25] | 62 | RME | 16 (+ 10) | - | - | 30 (+ 14) | - | - | 2~ (3.2) | 4 (6.5) | 17 (27.4) | 16 (25.8) | 24 (38.7) | 0 (0) |
| 147 | LME | 16 (+ 9) | - | - | 25 (+ 16) | - | - | 4~ (2.7) | 6 (4.1) | 55 (37.7) | 35 (24) | 46(31.5) | 4 (2.7) |
| Park *et al*[24] | 40 | RME | 12.9 (+7.5) | - | 198 (+ 69) | 14 (+ 9) | 0 (0) | 6.2 (4.7) | 3~ (7.5) | 0 (0) | 19 (47.5) | 9 (22.5) | 11 (27.7) | 1 (2.5) |
| 40 | LME | 13.3 (+8.6) | - | 213 (+ 139) | 13 (+ 9) | 0 (0) | 6.9 (5.1) | 2~ (5) | 0 (0) | 13 (32.5) | 15 (37.5) | 11 (27.5) | 1 (2.5) |
| Kim *et al*[26] | 30 | RME | - | 29 | - | 27.9 (+ 10.2) | 0 (0) | - | 2 (6) | - | - | - | - | - |
| 39 | LME | - | 37 | - | 28.6 (+ 13.6) | 0 (0) | - | 1 (2.5) | - | - | - | - | - |
| Bertani *et al*[27] | 52 | RME | 20.5 (5-43)1 | - | - | 26 (1-70) | - | - | 2 (4) | - | - | - | - | - |
| 34 | OME | 16 (6-46)1 | - | - | 26 (1-80) | - | - | 2 (6) | - | - | - | - |  |
| Kwak *et al*[28] | 59 | RME | 20 (12-27)1 | - | - | 22 (15-30) | 0 (0) | - | 1 (1.7) | 3 (5.1) | 16 (27.1) | 23 (39) | 13 (22) | 4 (6.8) |
| 59 | LME | 21 (14-28)1 | - | - | 20 (12-35) | 0 (0) | - | 0 (0) | 3 (5.1) | 16 (27.1) | 23 (39) | 12 (20.3) | 5 (8.5) |
| Baek *et al*[29] | 41 | RME | 13.1 (3.33) | - | - | 36 (4-100) | 0 (0) | - | 1 (2.4) | 7 (17.1) | 12 (29.3) | 4 (9.8) | 15 (36.6) | 3 (7.3) |
| 41 | LME | 16.2 (5-39) | - | - | 38 (4-110) | 0 (0) | - | 2 (4.9) | 3 (7.3) | 15 (36.6) | 3 (7.3) | 19 (46.3) | 1 (2.4) |
| Park *et al*[30] | 52 | RME | 19.4 (+ 10.2) | - | 165 (+ 60) | 28 (+ 19) | 0 (0) | 7.9 (+ 4.5) | 1~ (1.9) | 0 (0) | 15 (28.8) | 15 (28.8) | 22 (42.3) | 0 (0) |
| 123 | LME | 15.9 (+ 10.1) | - | 169 (+ 84) | 32 (+ 21) | 0 (0) | 8.2 (+ 5.8) | 3~(2.4) | 0 (0) | 34 (27.6) | 52 (42.3) | 37 (30.1) | 0 (0) |
| 88 | OME | 18.5 (+ 10.9) | - | 124 (+ 66) | 23 (+ 15) | 0 (0) | 8.5 (+ 5.7) | 2~ (2.3) | 0 (0) | 27 (30.7) | 32 (36.4) | 29 (33) | 0 (0) |
| Patriti *et al*[31] | 29 | RME | 10.3 (+ 4) | - | - | 21 (+ 9) | - | - | - | 0 (0) | 11 (38) | 9 (31) | 7 (24.1) | 2 (6.9) |
| 37 | LME | 11.2 (+ 5) | - | - | 45 (+ 72) | - | - | - | 0 (0) | 17 (46) | 8 (21.6) | 10 (27.2) | 2 (5.4) |
| Baik *et al*[32] | 18 | RME | 20 (6-49) | 17 | 109 (75-200) | 40 (10-55) | - |  | - | 0 (0) | 5 (27.8) | 4 (22.2) | 9 (50) | 0 (0) |
| 18 | LME | 17.4 (9-42) | 13 | 103 (55-85) | 37 (15-60) | - | - | - | 0 (0) | 5 (27.8) | 4 (22.2) | 9 (50) | 0 (0) |
| Pigazzi *et al*[33] | 6 | RME | 14 (9-28) | - | - | 38 (18-90) | - | - | - | - | - | - | - | - |
| 6 | LME | 17 (9-39) | - | - | 35 (22-50) | - | - | - | - | - | - | - | - |
| Parisi *et al*[34] | 40  | RME | 19 (6-35)1 | 32 | 118.5 (65-390)1 | 40 (20-80)1 | 0 (0) | - | - | 2 (5) | 10 (25) | 9 (22.5) | 19 (47.5) | 0 (0) |
| Baek *et al*[35] | 182 | RME | 14.8 (2-47) | - | - | 22 (+ 14.3) | - | - | 10~ (5.5) | 5 (2.7) | 57 (31.3) | 52 (28.5) | 62 (34) | 6 (3.3) |
| Shiomi *et al*[36] | 113 | RME | 32 (11-112)1 | 113 | 180 (65-376) | 26 (5-100) | 0 (0) | - | 0 (0) | 5 (4.4) | 35 (31) | 28 (24.7) | 38 (33.6) | 7 (6.2) |
| Kim *et al*[37] | 200 | RME | 16.1  | - | 132.5 | 22 | 0 (0) | - | 2 (1) | - | - | - | - | - |
| Stanciulea *et al*[38] | 100 | RME | 14 (4-32)1 | - | - | 30 (2-70)1 | - | - | - | 5 (5) | 24 (24) | 43 (43) | 21 (21) | 7 (7) |
| Stanciulea *et al*[38] | 77 | RME | 12.9 (3-45) | - | - | - | 2 (2.6) | - | 1 (1.2) | 26 (34) | 8 (10) | 15 (19) | 26 (34) | 2 (3) |
| Sng *et al*[40] | 197 | RME | 16 (1-80)1 | - | - | 17 (0-8.3)1 | - | - | 2 (2.5) | - | - | - | - | - |
| Du *et al*[41] | 22 | RME | 14.3 (8-27)1 | 19 | - | 26 (10-55) | - | - | - | 0 (0) | 1 (4.5) | 9 (40.9) | 12 (54.5) | 0 (0) |
| Alimoglu *et al*[42] | 7 | RME | 16 (14-21) | - | - | - | - | - | 0 (0) | 0 (0) | 3 (42.8) | 1 (14.2) | 3 (42.8) | 0 (0) |
| Akmal *et al*[43] | 80 | RME | 14.2 (2-33) | - | - | 32.5 (2-100) | - | 1.8 (0-45) | - | 15 (18.8) | 20 (25) | 12 (15) | 27 (33.8) | 5 (6.3) |
| Park *et al*[44] | 30 | RME | 20 (14-25)1 | 25 | - | - | - | 11 (5-20) | 0 (0) | 6 (20) | 7 (23.3) | 4 (13.3) | 10 (33.3) | 3 (10) |
| Kang *et al*[45] | 389 | RME | 15.7 (+ 10) | - | 11.7  | 2.15 | - | - | 14 (3.6) | 24 (6.2) | 122 (31.4) | 103 (26.5) | 140 (36) | 0 (0) |
| deSouza *et al*[46] | 44 | RME | 14 (5-45) | - | - | - | 1 (2.7) | - | 0 (0) | 4 (9.1) | 14 (31.8) | 15 (34.1) | 8 (18.2) | 3 (6.8) |
| Pigazzi *et al*[47] | 143 | RME | 14.1 (1-39) | - | - | 29 (0-100) | - | 19 (1-45) | 1 (0.7) | 18 (12.6) | 36 (25.2) | 36 (25.2) | 53 (37) | 0 (0) |
| Choi *et al*[48] | 50 | RME | 20.6 (6-48) | - | - | 19 (5-45) | 0 (0) | - | 1 (2) | 0 (0) | 10 (20) | 19 (38) | 19 (38) | 2 (4) |
| Ng *et al*[49] | 8 | RME | 15 (2-26)1 | - | - | - | - | - | 0 (0) | 0 (0) | 3 (37.5) | 2 (25) | 2 (25) | 0 |
| Hellan *et al*[50] | 39 | RME | 13 (7-28)1 | - | - | 26.5 (4-75)1 | 0 (0) | - | 0 (0) | 8 (20.5) | 13 (33.3) | 4 (10.3) | 13 (33.3) | 1 (2.6) |

1Median.

 **Table 8 Short term oncologic outcomes**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Pts**  | **Mesorectum** | **DSF% (yr)** | **LR (%)** | **Distant mtx (%)** | **OS % (yr)** | **F-u mo (median)** |
| Park *et al*[8] | 133 | RME | 81.9 (5) | 3 (2.3) | 16 (12) | 92.8 (5) | 58 (4-80) |
| 84 | LME | 78.7 (5) | 1 (1.2) | 14 (16.6) | 93.5 (5) | 58 (4-80) |
| Levic *et al*[9] | 56 | RME |  | 0 (0) | 8 (14.3) |  | 12 (1-31) |
| 36 | LME |  | 0 (0) | 2 (5.6) |  | 10 (1-33) |
| Yoo *et al*[10] | 431 | RME | 76.7 (3) | 6 (12.8) |  | 95.2 (3) | 33.9 (4.4-61.3) |
| 26 | LME | 75 (3) | 2 (8.3) |  | 88.5 (3) | 36.5 (3.7-69.9) |
| Ghezzi *et al*[16] | 65 | RME | 73.2 (5) | 2 (3.2) |  19 (29.6) | 85 (5) | 60 |
| 109 | OME | 69.5 (5) | 17.5 (16.1) |  26 (24.2) | 76.1 (5) | 60 |
| Saklani *et al*[19] | 74 | RME | 77.7 (3) | 2 (2.7) |  | 90 (3) | 30.1 (11-61)2 |
| 64 | LME | 78.8 (3) | 4 (6.3) |  | 92.1 (3) | 30.1 (11-61)2 |
| Kim *et al*[25] | 62 | RME |  | 0 (0) | 3 (4.2) | 98 (1,5) | 17.4 |
| 147 | LME |  | 1 (0.7) | 8 (5.4) | 98 (1.7) | 20.6 |
| Kwak *et al*[28] | 59 | RME |  | 1 (1.8) | 2 (3.6) |  | 17 (11-25) |
| 59 | LME |  | 1 (1.9) | 2 (3.7) |  | 13 (9-22) |
| Patriti *et al*[31] | 29 | RME | 100 (3) | 0 (0) | 0 (0) | 96.6 (2.4) | 29.22 |
| 37 | LME | 83.7 (3) | 2 (5.4) | 4 (6) | 97.2 (1.5) | 18.72 |
| Stanciulea *et al*[38] | 100 | RME |  | 2 (2) |  | 90 (3) | 24 (9-63) |
| Alimoglu *et al*[42] | 7 | RME | 100 (1) | 0 (0) | 0 (0) | 100 (1) | 12 (6-21)2 |
| Pigazzi *et al*[47] | 143 | RME | 77.6 (3) | 2 (1.4) | 13 (9) | 97 (3) | 17.4 (0.1-52.5)2 |

11 patient excluded (palliative ISR); 2 Mean. DSF: Disease free survival rate.